PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/00, 1/68, G01N 33/53	A1	(11) International Publication Number: **WO 99/09204** (43) International Publication Date: 25 February 1999 (25.02.99)

(21) International Application Number: PCT/US98/17135 (22) International Filing Date: 18 August 1998 (18.08.98) (30) Priority Data: 08/919,187 19 August 1997 (19.08.97) US (71)(72) Applicant and Inventor: WOODS, Virgil, L., Jr. [US/US]; 2920 Union Street #103, San Diego, CA 92103 (US). (74) Agents: GISOLFI, Ann, L. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). **Published** *With international search report.*

(54) Title: METHODS FOR THE HIGH-RESOLUTION IDENTIFICATION OF SOLVENT-ACCESSIBLE AMIDE HYDROGENS IN POLYPEPTIDES

(57) Abstract

The present invention provides methods whereby the positions of peptide amide groups that are labeled with a heavy hydrogen in a polypeptide or protein can be localized at high resolution. The methods are useful for determining which peptide amide groups in a polypeptide or protein are accessible to solvent, mapping the binding site and/or binding surface of a binding protein, and/or studying allosteric or other conformational changes in a polypeptide or protein which alter the rates at which certain peptide amide hydrogens exchange with solvent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR THE HIGH-RESOLUTION IDENTIFICATION OF SOLVENT-ACCESSIBLE AMIDE HYDROGENS IN POLYPEPTIDES

—

5   This application is a continuation-in-part of application Serial No. 08/895,330, entitled "Methods for Characterization of the Fine Structure of Protein Binding Sites", filed July 16, 1997 (attorney docket no. 9300-004-999), which is a continuation of application Serial No.

10 08/240,593, filed May 10, 1994, each of which is hereby incorporated herein in its entirety by reference.

BACKGROUND OF THE INVENTION

15 Field of the Invention

The present invention relates to the identification of solvent-accessible amide hydrogens in polypeptides or proteins. The methods of the invention can be used to characterize the binding site involved in binding between a

20 binding protein and a binding partner, and to study other changes in a polypeptide or protein which alter the rates at which hydrogen atoms exchange with solvent hydrogens, such as folding phenomena and other structural changes.

25 Background Art

Limitations of Current Methods of Characterizing Protein Binding Sites.

Considerable experimental work and time are required to precisely characterize a binding site. In general, the

30 techniques which are the easiest to use and which give the quickest answers, result in an inexact and only approximate idea of the nature of the critical structural features. Techniques in this category include the study of proteolytically generated fragments of the protein which

35 retain binding function; recombinant DNA techniques, in which proteins are constructed with altered amino acid sequence (site directed mutagenesis); epitope scanning peptide studies

(construction of a large number of small peptides
representing subregions of the intact protein followed by
study of the ability of the peptides to inhibit binding of
the ligand to receptor); covalent crosslinking of the protein
5 to its binding partner in the area of the binding site,
followed by fragmentation of the protein and identification
of crosslinked fragments; and affinity labeling of regions of
the receptor which are located near the ligand binding site
of the receptor, followed by characterization of such
10 "nearest neighbor" peptides. (Reviewed in 1, 2).

These techniques work best for the determination of the
structure of binding subregions which are simple in nature,
as when a single short contiguous stretch of polypeptide
within a protein is responsible for most of the binding
15 activity. However, for many protein-binding partner systems
of current interest, the structures responsible for binding
on both receptor and ligand or antibody are created by the
complex interaction of multiple non-contiguous peptide
sequences. The complexities of these interactions may
20 confound conventional analytical techniques, as binding
function is often lost as soon as one of the 3-dimensional
conformations of the several contributing polypeptide
sequences is directly or indirectly perturbed.

The most definitive techniques for the characterization
25 of the structure of receptor binding sites have been NMR
spectroscopy and X-ray crystallography. While these
techniques can ideally provide a precise characterization of
the relevant structural features, they have major
limitations, including inordinate amounts of time required
30 for study, inability to study large proteins, and, for X-ray
analysis, the need for protein-binding partner crystals (Ref.
3).

Applicant's technology overcomes these limitations and
allows the rapid identification of each of the specific
35 polypeptides and amino acids within a protein which
constitute its protein ligand binding site or antibody
binding subregion in virtually any protein-ligand system or

- 2 -

protein antigen-antibody system, regardless of the complexity
of the binding sites present or the size of the proteins
involved. This technology is superior in speed and
resolution to currently employed biochemical techniques.

5

Hydrogen (Proton) Exchange.

When a protein in its native folded state is
incubated in buffers containing heavy hydrogen (tritium or
deuterium) labeled water, heavy hydrogen in the buffer
10 reversibly exchanges with normal hydrogen present in the
protein at acidic positions (for example, O-H, S-H, and N-H
groups) with rates of exchange which are dependent on each
exchangeable hydrogen's chemical environment, temperature,
and most importantly, its accessibility to the tritiated
15 water in the buffer. (Refs. 4, 5) Accessibility is
determined in turn by both the surface (solvent-exposed)
disposition of the hydrogen, and the degree to which it is
hydrogen-bonded to other regions of the folded protein.
Simply stated, acidic hydrogen present on amino acid residues
20 which are on the outside (buffer-exposed) surface of the
protein and which are hydrogen-bonded to solvent water will
exchange more rapidly with heavy hydrogen in the buffer than
will similar acidic hydrogen which are buried and hydrogen-
bonded within the folded protein.
25   Hydrogen exchange reactions can be greatly accelerated
by both acid and base-mediated catalysis, and the rate of
exchange observed at any particular pH is the sum of both
acid and base mediated mechanisms. For many acidic hydrogen,
a pH of 2.7 results in an overall minimum rate of exchange
30 (Ref. 6, pg. 238, FIGS. 3a-c, refs. 7-11). While hydrogens
in protein hydroxyl and amino groups exchange with tritium in
buffer at millisecond rates, the exchange rate of one
particular acidic hydrogen, the peptide amide bond hydrogen,
is considerably slower, having a half life of exchange (when
35 freely hydrogen bonded to solvent water) of approximately 0.5
seconds at 0°C, pH 7, which is greatly slowed to a half life
of exchange of 70 minutes at 0°C pH 2.7.

- 3 -

When peptide amide hydrogens are buried within a folded
protein, or are hydrogen bonded to other parts of the
protein, exchange half lives with solvent hydrogens are often
considerably lengthened, at times being measured in hours to
5 days. Hydrogen exchange at peptide amides is a fully
reversible reaction, and rates of on-exchange (solvent heavy
hydrogen replacing protein-bound normal hydrogen) are
identical to rates of off-exchange (hydrogen replacing
protein-bound heavy hydrogen) if the state of a particular
10 peptide amide within a protein, including its chemical
environment and accessibility to solvent hydrogens, remains
identical during on-exchange and off-exchange conditions.

Hydrogen exchange is commonly measured by performing
studies with proteins and aqueous buffers that are
15 differentially tagged with pairs of the three isotopic forms
of hydrogen (^{1}H;Normal Hydrogen; ^{2}H;Deuterium; ^{3}H;Tritium).
If the pair of normal hydrogen and tritium are employed, it
is referred to as tritium exchange; if normal hydrogen and
deuterium are employed, as deuterium exchange. Different
20 physicochemical techniques are in general used to follow the
distribution of the two isotopes in deuterium versus tritium
exchange.

Tritium Exchange Techniques
25 Tritium exchange techniques (where the amount of the
isotope is determined by radioactivity measurements) have
been extensively used for the measurement of peptide amide
exchange rates within an individual protein (reviewed in 4).
The rates of exchange of other acidic protons (OH, NH, SH)
30 are so rapid that they cannot be followed in these techniques
and all subsequent discussion refers exclusively to peptide
amide proton exchange. In these studies, purified proteins
are on-exchanged by incubation in buffers containing
tritiated water for varying periods of time, transferred to
35 buffers free of tritium, and the rate of off-exchange of
tritium determined. By analysis of the rates of tritium on-
and off-exchange, estimates of the numbers of peptide amide

- 4 -

protons in the protein whose exchange rates fall within
particular exchange rate ranges can be made. These studies
do not allow a determination of the identity (location within
the protein's primary amino acid sequence) of the exchanging
5 amide hydrogens measured.

Extensions of these techniques have been used to detect
the presence within proteins of peptide amides which
experience allosterically-induced changes in their local
chemical environment and to study pathways of protein folding
10 (5, 12-14). For these studies, tritium on-exchanged proteins
are allowed to off-exchange after they have experienced
either an allosteric change in shape, or have undergone time-
dependent folding upon themselves, and the number of peptide
amides which experience a change in their exchange rate
15 subsequent to the allosteric/folding modifications
determined. Changes in exchange rate indicate that
alterations of the chemical environment of particular peptide
amides have occurred which are relevant to proton exchange
(solvent accessibility, hydrogen bonding etc.). Peptide
20 amides which undergo an induced slowing in their exchange
rate are referred to as "slowed amides" and if previously on-
exchanged tritium is sufficiently slowed in its off-exchange
from such amides there results a "functional tritium
labeling" of these amides. From these measurements,
25 inferences are made as to the structural nature of the shape
changes which occurred within the isolated protein. Again,
determination of the identity of the particular peptide
amides experiencing changes in their environment is not
possible with these techniques.
30   Four groups of investigators have described technical
extensions (collectively referred to as medium resolution
tritium exchange) which allow the locations of particular
slowed, tritium labeled peptide amides within the primary
sequence of small proteins to be localized to a particular
35 proteolytic fragment, though not to a particular amino acid.

- 5 -

Rosa and Richards were the first to describe and utilize
medium resolution tritium techniques in their studies of the
folding of ribonuclease S protein fragments (15-17).
However, the techniques described by Rosa and Richards were

5 of marginal utility, primarily due to their failure to
optimize certain critical experimental steps (reviewed in 6,
pg 238, 244). No studies employing related techniques were
published until the work of Englander and co-workers in which
extensive modifications and optimizations of the Rosa and

10 Richards technique were first described.

Englander's investigations utilizing tritium exchange
have focused exclusively on the study of allosteric changes
which take place in tetrameric hemoglobin (a subunit and b
subunit 16 kD in size each) upon deoxygenation (6,18-21). In

15 the Englander procedure, native hemoglobin (milligram
quantities) in the oxygenated state is on-exchanged in
tritiated water of relatively low specific activity (2-100
mCi/ml). The hemoglobin is then deoxygenated (inducing
allosteric change), transferred to tritium-free buffers by

20 gel permeation column chromatography, and then allowed to
out-exchange for 10-50 times the on-exchange time. On-
exchanged tritium present on peptide amides which experience
no change in exchange rate subsequent to the induced
allosteric change in hemoglobin structure off-exchanges at

25 rates identical to its on-exchange rates, and therefore is
almost totally removed from the protein after the long off-
exchange period. However, peptide amides which experience
slowing of their exchange rate subsequent to the induced
allosteric changes preferentially retain the tritium label

30 during the period of off-exchange.

To localize (in terms of hemoglobin's primary sequence)
the slowed amides bearing the residual tritium label,
Englander then proteolytically fragments the off-exchanged
hemoglobin with the protease pepsin, separates, isolates and

35 identifies the various peptide fragments by reverse phase
high pressure liquid chromatography (RP-HPLC), and determines
which fragments bear the residual tritium label by

- 6 -

scintillation counting. However, as the fragmentation of
hemoglobin proceeds, each fragment's secondary and tertiary
structure is lost and the unfolded peptide amides become
freely accessible to H_2O in the buffer. At physiologic pH

5 (>6), any amide-bound tritium label would leave the unfolded
fragments within seconds. Englander therefore performs the
fragmentation and HPLC peptide isolation procedures under
conditions which he believes minimize peptide amide proton
exchange, including cold temperature (4°C) and use of

10 phosphate buffers at pH 2.7 (reviewed in 6). This technique
has been used successfully by Englander to coarsely identify
and localize the peptidic regions of hemoglobin α and β
chains which participate in deoxygenation-induced allosteric
changes (18-21). The ability of the Englander technique to

15 localize tritium labeled amides, while an important advance,
remains low; at the best, Englander reports that his
technique localizes amide tritium label to hemoglobin
peptides 14 amino acids or greater in size, without the
ability to further sublocalize the label.

20   Moreover, in Englander's work, there is no appreciation
that a suitably adapted tritium exchange technique might be
used to identify the peptide amides which reside in the
contacting surface of a protein receptor and its binding
partner: his disclosures are concerned exclusively with the

25 mapping of allosteric changes in hemoglobin. Furthermore,
based on his optimization studies (6-11,13), Englander
teaches and warns that a pH of 2.7 must be employed in both
the proteolysis and HPLC steps, necessitating the use of
proteases which are functional at these pH's (acid

30 proteases). Unfortunately, acid proteases are relatively
nonspecific in their sites of proteolytic cleavage, leading
to the production of a very large number of different peptide
fragments and hence to considerable HPLC separation
difficulties. The constraint of performing the HPLC

35 separation step at pH 2.7 greatly limits the ability to
optimize the chromatographic separation of multiple
overlapping peptides by varying the pH at which HPLC is

- 7 -

performed. Englander tried to work around these problems,
for the localization of hemoglobin peptides experiencing
allosteric changes, by taking advantage of the fact that some
peptide bonds are somewhat more sensitive to pepsin than

5 others. He therefore limits the duration of exposure of the
protein to pepsin to reduce the number of fragments. Even
then the fragments were "difficult to separate cleanly".
They were also, of course, longer (on average), and therefore
the resolution was lower. He also tried to simplify the

10 patterns by first separating the alpha and beta chains of
hemoglobin. However, there was a tradeoff: increased tritium
loss during the alpha-beta separation and the removal of the
solvent, preparatory to proteolysis. Englander concludes,

15   "At present the total analysis of the HX (hydrogen
           exchange) behavior of a given protein by these
           methods is an immense task. In a large sense, the
           best strategies for undertaking such a task remain
           to be formulated. Also, these efforts would

20   benefit from further technical improvements, for
           example in HPLC separation capability and perhaps
           especially in the development of additional acid
           proteases with properties adapted to the needs of
           these experiments" (6).

25

       Over the succeeding years since this observation was
made, no advances have been disclosed which address these
critical limitations of the medium resolution tritium
exchange technique. It has been perceived that improvements

30 to the HPLC separation step were problematic due to the
constraint of working at pH 2.7. The current limited success
with small proteins has made it pointless to attempt similar
studies of larger proteins where the problems of inadequate
HPLC peptide separation at pH 2.7, and imprecision in the

35 ability to sublocalize labeled amides would be greatly
compounded. Furthermore, most acid-reactive proteases are in
general no more specific in their cleavage patterns than

- 8 -

pepsin and efforts to improve the technology by employing
other acid reactive proteases other than pepsin have not
significantly improved the technique. Given these
limitations of medium resolution tritium exchange art, no
5 studies have been disclosed which utilize proteins with
subunit size greater than 16 kilodaltons.

Allewell and co-workers have disclosed studies utilizing
the Englander techniques to localize induced allosteric
changes in the enzyme escherichia coli aspartate
10 transcarbamylase (22,23). Burz, et al. (22) is a brief
disclosure in which the isolated R2 subunit of this enzyme is
on-exchanged in tritiated buffer of specific activity 100
mCi/ml, allosteric change induced by the addition of ATP, and
then the conformationally altered subunit off-exchanged. The
15 enzyme R2 subunit was then proteolytically cleaved with
pepsin and analyzed for the amount of label present in
certain fragments. Analysis employed techniques which
rigidly adhered to the recommendations of Englander,
utilizing a single RP HPLC separation in a pH 2.8 buffer.
20   The authors note difficulty in separating the large
number of peptides generated, even from this small protein
subfragment, given the constraints of the Englander
methodology. They comment that "the principal limitation of
this method at present is the separation with columns now
25 available". ATP binding to the enzyme was shown to alter the
rate of exchange of hydrogens within several relatively large
peptidic fragments of the R2 subunit. In a subsequent more
complete disclosure (23), the Allewell group discloses
studies of the allosteric changes induced in the R2 subunit
30 by both ATP and CTP. They disclose on-exchange of the R2
subunit in tritiated water-containing buffer of specific
activity 22-45 mCi/ml, addition of ATP or CTP followed by off
exchange of the tritium in normal water-containing buffer.
The analysis comprised digestion of the complex with pepsin,
35 and separation of the peptide fragments by reverse phase HPLC
in a pH 2.8 or pH 2.7 buffer, all of which rigidly adheres to
the teachings of Englander. Peptides were identified by

- 9 -

amino acid composition or by N-terminal analysis, and the
radioactivity of each fragment was determined by
scintillation counting. In both of these studies the
localization of tritium label was limited to peptides which
5 averaged 10-15 amino acids in size, without higher resolution
being attempted.

Beasty, et al. (24) have disclosed studies employing
tritium exchange techniques to study folding of the a subunit
of E. Coli tryptophan synthetase. The authors employed
10 tritiated water of specific activity 20 mCi/ml, and
fragmented the tritium labeled enzyme protein with trypsin at
a pH 5.5, conditions under which the protein and the large
fragments generated retained sufficient folded structure as
to protect amide hydrogens from off exchange during
15 proteolysis and HPLC analysis. Under these conditions, the
authors were able to produce only 3 protein fragments, the
smallest being 70 amino acids in size. The authors made no
further attempt to sublocalize the label by further digestion
and/or HPLC analysis. Indeed, under the experimental
20 conditions they employed (they performed all steps at 12°C
instead of 4°C, and performed proteolysis at pH 5.5 instead
of pH in the range of 2-3), it would have been impossible to
further sublocalize the labeled amides by tritium exchange,
as label would have been immediately lost (off-exchanged) by
25 the unfolding of subsequently generated proteolytic fragments
at pH 5.5 if they were less than 10-30 amino acids in size.

Fromageot, et al., U.S. Patent 3,828,102 (25) discloses
using hydrogen exchange to tritium label a protein and its
binding partner, and Benson, U.S. Patents 3,560,158 and
30 3,623,840 (26) disclose using hydrogen exchange to tritiate
compounds for analytical purposes.

However, none of the methods described in the art are
capable of localizing the positions of the tritium labels of
the labeled proteins at high resolution, the best resolution
35 in the art generally being on the order of ≥14 amino acid
residues.

- 10 -

Deuterium Exchange Techniques

      Fesik, et al (27) discloses measuring by NMR the
hydrogen (deuterium) exchange of a peptide before and after
it is bound to a protein. From this data, the interactions
5 of various hydrogens in the peptide with the binding site of
the protein are analyzed.

      Patterson, et al. (28) and Mayne, et al. (29) disclose
NMR mapping of an antibody binding site on a protein
(cytochrome-C) using deuterium exchange. This relatively
10 small protein, with a solved NMR structure, is first
complexed to anti-cytochrome-C monoclonal antibody, and the
preformed complex then incubated in deuterated water-
containing buffers and NMR spectra obtained at several time
intervals. The NMR spectra of the antigen-antibody complex
15 is examined for the presence of peptide amides which
experience slowed hydrogen exchange with solvent deuterium as
compared to their rate of exchange in uncomplexed native
cytochrome-C. Benjamin, et al. (30) employ an identical NMR-
deuterium technique to study the interaction of hen egg
20 lysozyme (HEL) with HEL-specific monoclonal antibodies.
While both this NMR-deuterium technique, and medium
resolution tritium exchange rely on the phenomenon of proton
exchange at peptide amides, they utilize radically different
methodologies to measure and localize the exchanging amides.
25 Furthermore, study of proteins by the NMR technique is not
possible unless the protein is small (less than 30 kD), large
amounts of the protein are available for the study, and
computationally intensive resonance assignment work is
completed.

30   Recently, others (45-50) have disclosed techniques in
which exchange-deuterated proteins are incubated with binding
partner, off-exchanged, the complex fragmented with pepsin,
and deuterium-bearing peptides identified by single stage
fast atom bombardment (Fab) or electrospray mass spectroscopy
35 (MS). In these studies, no attempt has been made to
sublocalize peptide-bound deuterium within the
proleolytically or otherwise generated peptide fragments.

- 11 -

Thus, as is evidenced by the above discussion, there
remains a need in the art for simple and efficient methods
whereby the positions of labeled solvent-accessible peptide
amide hydrogens can be localized at high resolution within
5 the primary amino acid sequence of a polypeptide or protein,
as well as simple and efficient methods for studying or
mapping the binding sites and/or interaction surfaces of a
polypeptide or protein. Accordingly, these are objects of
the present invention.
10

SUMMARY OF THE INVENTION

These and other shortcomings in the art are overcome by
the present invention, which in one aspect provides methods
for the functional labeling and identification of specific
15 amino acid residues that participate in binding protein-
binding partner interactions. The methods of the invention
are particularly suitable for the study of the binding
protein-binding partner subregions of large (>30 KD)
proteins, even in small quantities.
20   In one embodiment, the label is tritium and the amount
of label on a fragment or subfragment is determined by
measuring its radioactivity. In a second embodiment, the
label is deuterium and the amount of label on a fragment or
subfragment is determined by mass spectrometry. The term
25 "heavy hydrogen" is used herein to refer generically to
either tritium or deuterium. In addition, references to
tritium apply mutatis mutandis to deuterium except when
clearly excluded.

In essence, the binding protein is first tritiated or
30 deuterated under conditions wherein native hydrogens are
replaced by the tritium or deuterium label (this is the "on-
exchange" step). Then the binding partner is allowed to
interact with labeled protein. The binding partner occludes
the binding site and protects the tritium or deuterium labels
35 of that site from a subsequent "off-exchange". Thus, after
the "off-exchange", only the binding site residues are
labeled. Since the binding site is normally only a small

- 12 -

portion of the molecules, a higher signal-to-background ratio
is obtained with this approach than with Englander's more
conventional procedure.

In order to actually identify the labeled residues, one
5 must first dissociate the complex under slow hydrogen isotope
exchange (H^3/H^1 or H^2/H^1) conditions, since otherwise the
labels would leave the binding site as soon as the ligand was
removed. The binding protein is then optionally fragmented
(e.g., with an endoprotease such as pepsin), still under slow
10 hydrogen exchange conditions, to obtain fragments. Those
fragments which bear label presumably include binding site
residues. At this point, the resolution of the binding site
is no better than the fragment size.

A finer localization of the labels is achieved by
15 analysis of subfragments generated by controlled, stepwise,
degradation of the binding protein or of each isolated,
labeled peptide fragment (if the binding protein was
optionally fragmented) under slowed exchange conditions. For
the purpose of the present invention, the protein or a
20 peptide fragment is said to be "progressively", "stepwise"
or "sequentially" degraded if a series of fragments are
obtained which are similar to those which would be achieved
by an ideal exopeptidase. For an ideal exopeptidase, only an
end amino acid is removed. Thus, if the n amino acids of a
25 peptide were labeled A_1 to A_n (the numbering starting at
whichever end the degradation begins), the series of
subfragments produced by an ideal exopeptidase would be
$A_2...A_n$, $A_3...A_n$, ..., $A_{n-1}-A_n$, and finally A_n. However, it is to
be understood that while preferably each subfragment of the
30 series of subfragments obtained is shorter than the preceding
subfragment in the series by a single terminal amino acid
residue, exopeptidases are not necessarily ideal. Thus, for
purposes of the present invention, a fragment is said to be
"progressively," "stepwise" or "sequentially" degraded if a
35 series of subfragments is generated wherein each subfragment
in the series is composed of about 1-5 fewer terminal amino
acid residues than the preceding subfragment in the series.

- 13 -

The signals produced by the successive subfragments are correlated in order to determine which amino acids of the fragment in question were labeled.

This procedure was not used in any of the cited
5 references to further localize the labeling sites, though improved resolution was certainly a goal of the art. The closest the art comes is Englander's general suggestions of further fragmentations with another "acid protease".

The progressive degradation is preferably achieved by an
10 enzyme, and more preferably by a carboxypeptidase. The need to employ an acidic pH at the time of degradation to minimize tritium losses discourages use of carboxypeptidases which are substantially inactivated by the required acidic buffers. However, carboxypeptidase-P, carboxypeptidase Y, and several
15 other acid - reactive (i.e., enzymatically active under acid conditions) carboxypeptidases are suitable for proteolysis of peptides under acidic conditions, even at pH 2.7.

Progressive subfragmentation of purified tritium label-bearing peptides is performed with acid-reactive
20 carboxypeptidases under conditions that produce a complete set of amide-labeled daughter peptides each shorter than the preceding one by 1-5 carboxy terminal amino acids, and preferably by a single carboxy-terminal amino acid. HPLC analysis of the several members of this set of progressively
25 truncated peptides allows the reliable assignment of label to a particular amide position within the parent peptide.

Alternatively, the present invention contemplates C-terminal chemical degradation techniques that can be performed under "slow hydrogen exchange conditions" e.g., by
30 pentafluoropropionic acid anhydride. The sensitivity of the technique may be improved by the use of reference peptide subfragments as HPLC mobility markers.

In general, the art has given insufficient consideration to the problems of denaturing the binding protein
35 sufficiently to facilitate proteolysis under slow hydrogen exchange conditions. Pepsin, for example, is much less active at 0°C. than at room temperature. While pepsin is

- 14 -

able to extensively digest hemoglobin that has been denatured
by acidic pH at 0°C, certain other binding proteins, such as
hen egg lysozyme, are much more resistant to denaturation by
slow H-exchange conditions, and hence to subsequent pepsin

5   digestion. As a result, many fewer and longer fragments are
generated. This complicates the analysis.

In a preferred embodiment, the labeled binding protein
is exposed, before fragmentation, to denaturing conditions
compatible with slow hydrogen exchange and sufficiently

10 strong to denature the protein enough to render it adequately
susceptible to the intended proteolytic treatment. If these
denaturing conditions would also denature the protease, then,
prior to proteolysis, the denatured protein is switched to
less denatured conditions (still compatible with slow H-

15 exchange) sufficiently denaturing to maintain the protein in
a protease-susceptible state but substantially less harmful
to the protease in question.

Preferably, the initial denaturant is guanidine
thiocyanate, and the less denaturing condition is obtained by

20 dilution with guanidine HCl.

Disulfide bonds, if present in the binding protein to be
digested, can also interfere with analysis. Disulfide bonds
can hold the protein in a folded state where only a
relatively small number of peptide bonds are exposed to

25 proteolytic attack. Even if some peptide bonds are cleaved,
failing to disrupt the disulfide bonds would reduce
resolution of the peptide fragments still joined to each
other by the disulfide bond; instead of being separated, they
would remain together. This would reduce the resolution by

30 at least a factor of two (possibly more, depending on the
relationship of disulfide bond topology to peptide cleavage
sites). If the disulfide bonds are not disrupted, further
sublocalization of the tritium-labeled amides within each of
the disulfide-joined peptides would be very difficult, as

35 amino acid removal would occur, at different times and at
different rates, at each C-terminal of the disulfide linked
segments.

- 15 -

The applicant has discovered that water soluble
phosphines may be used to disrupt a protein's disulfide bonds
under "slow hydrogen exchange" conditions. This allows much
more effective fragmentation of large proteins which contain
5 disulfide bonds without causing tritium label to be lost from
the protein or its proteolytic fragments (as would be the
case with conventional disulfide reduction techniques which
must be performed at pH's which are very unfavorable for
preservation of tritium label).

10   In another embodiment, peptide amides on the binding
protein's surface are indirectly labeled by transfer of
tritium or deuterium that has been previously attached by
hydrogen exchange to the interaction surface of the binding
partner. This procedure will functionally label receptor
15 protein amides if they are slowed by complex formation and
are also in intimate contact with the binding partner, in the
complexed state. Amides that are distant from the
interaction surface but slowed in exchange because of complex
formation-induced allosteric changes in the protein will not
20 be labeled.

        In another aspect, the present invention provides a
method for determining which peptide amide hydrogens in a
polypeptide or protein are accessible to solvent. By using
the method of the invention, the positions of solvent-
25 accessible peptide amide hydrogens within a polypeptide or
protein can be localized at high resolution, *i.e.*, typically
within 5 or fewer amino acid residues, and in many instances
to within a single amino acid residue.

        In the method, solvent accessible peptide amide
30 hydrogens of a polypeptide or protein of interest are on-
exchanged by contacting the polypeptide or protein with heavy
hydrogen under conditions wherein the native solvent-
accessible peptide amide hydrogens are replaced with heavy
hydrogen (deuterium or tritium), such as, for example,
35 physiological conditions wherein the polypeptide or protein
is folded into its native conformation. Peptide amide
protons that are inaccessible to solvent, such as those that

- 16 -

are buried within the interior of the polypeptide or protein
structure or those that participate in intramolecular
hydrogen-bonding interactions, do not readily exchange with
the heavy hydrogens in the solvent. Thus, those peptide
5 amide hydrogens that are solvent-accessible are selectively
labeled with heavy hydrogen.

The positions of the labeled peptide amide hydrogens
within the polypeptide or protein can be localized at high
resolution by progressively generating a series of
10 subfragments under conditions of slowed exchange as
previously described, determining which subfragments are
labeled and correlating the sequences of the labeled
subfragments with the sequence of the polypeptide or protein
to determine which peptide amide groups in the polypeptide or
15 protein were labeled, and thus accessible to solvent.

In some embodiments, especially those wherein the
polypeptide or protein of interest is relatively large, the
polypeptide or protein may optionally be first fragmented
(e.g., with an endoprotease or mixture of endoproteases)
20 under conditions of slowed exchange as previously described,
and the positions of the labels localized to high resolution
by progressively degrading each labeled fragment into a
series of subfragments, determining which subfragments are
labeled and correlating the sequences of the labeled
25 subfragments to the sequences of the labeled fragments and,
ultimately, to the sequence of the polypeptide or protein, as
previously described.

In a preferred embodiment, the polypeptide or protein is
denatured and any disulfide bonds reduced under conditions of
30 slowed exchange prior to fragmentation and/or
subfragmentation.

BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1a-1d depict the results of analysis of tritium
35 associated with hemoglobin (Hgb) fragments produced by pepsin
digestion of tritium-exchanged hemoglobin ± monoclonal,
antibody followed by HPLC in PO_4 buffered solvents, pH 2.7.

- 17 -

FIG. 1a: Absorbance (214 nm) tracing of unlabeled
proteolyzed Hgb. FIG. 1b: Hgb on-exchanged for 4 hours,
shifted to pH 2.7 and then proteolyzed without off exchange.
FIG. 1c: Hgb on-exchanged for 4 hours, mixed with monoclonal
5 antibody β6 and then off-exchanged for 40 hours before
proteolysis at pH 2.7. FIG. 1d: Hgb on-exchanged for 4 hours
and then off-exchanged for 40 hours before proteolysis at pH
2.7.

10   FIG. 2 depicts the results of second dimension
separation (HPLC with 0.1% Trifluroracetic Acid (TFA)
containing solvents) at 0°C of tritium-bearing rpHPLC
fraction from first dimension separation, FIG. 1c.

15   FIGS. 3a-c show the identification of hemoglobin
peptides functionally labeled by interaction with monoclonal
antibody β-121.

        FIGS. 4a-d depict the identification of hemoglobin
20 peptides functionally labeled by interaction with
haptoglobin.

        FIGS. 5a-b show the structure of hemoglobin with
peptidic regions highlighted. FIG. 5A: β6 monoclonal
25 interaction peptides; FIG. 5B: β121 monoclonal interaction
peptides.

        FIGS. 6a-e depict the results of carboxypeptidase-P
digestion of β1-14 peptide. Tritium-exchange-labeled
30 synthetic β1-14 peptide was digested (0°C) with
carboxypeptidase-P (CP-P) using a range of enzyme
concentrations and digestion times (indicated at far left
margin). HPLC analysis as then performed as in FIGS. 1a-d,
but with simultaneous measurement of O.D.214 and
35 radioactivity of column effluent. The positions of the
several generated C-terminal truncated peptide fragments are

- 18 -

indicated (numbers 3 through 9). Progressive generation of
fragments is observed.

        FIGS. 7a-e depict the results of reduction of disulfide
5 bonds at pH 2.7. Tritium-exchange-labeled β1-14 peptide (2μg
   at 0°C, pH 2.7) was supplemented with the peptide endothelin
   (4μg), which contains two disulfide bonds (35), and the
   mixture incubated without (FIG. 7a) or with (FIGS. 7b-e) 50
   mM Tris (2-carboxyethyl) phosphine (TCEP) for varying times
10 at 0°C (FIGS. 7a, 7c-e), 2 minutes at 22°C (FIG. 7b). The
   mixtures were then subjected to HPLC as in FIGS. 6a-e. The
   percent of endothelin that remained unreduced under each
   condition is indicated as is the fraction of tritium label
   that remained attached to the β1-14 peptide. Fifty percent
15 reduction of endothelium disulfides is accomplished at pH 2.7
   with an insignificant loss of peptide amide-bound tritium
   from the β1-14 peptide. "R" indicates the positions of
   reduced forms of endothelin.

20 **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**
   Biochemical Binding, Generally.
        Many biological processes are mediated by noncovalent
   binding interactions between a protein and another molecule,
   its binding partner. The identification of the structural
25 features of the two binding molecules which immediately
   contribute to those interactions would be useful in designing
   drugs which alter these processes.
        The molecules which preferentially bind each other may
   be referred to as members of a "specific binding pair". Such
30 pairs include an antibody and its antigen, a lectin and a
   carbohydrate which it binds, an enzyme and its substrate, and
   a hormone and its cellular receptor. In some texts, the
   terms "receptor" and "ligand" are used to identify a pair of
   binding molecules. Usually, the term "receptor" is assigned
35 to a member of a specific binding pair which is of a class of
   molecules known for its binding activity, e.g., antibodies.
   The term "receptor" is also preferentially conferred on the

- 19 -

member of the pair which is larger in size, e.g., on avidin
in the case of the avidin-biotin pair. However, the
identification of receptor and ligand is ultimately
arbitrary, and the term "ligand" may be used to refer to a
5 molecule which others would call a "receptor". The term
"anti-ligand" is sometimes used in place of "receptor".

While binding interactions may occur between any pair of
molecules, e.g., two strands of DNA, the present
specification is primarily concerned with interactions in
10 which at least one of the molecules is a protein. Hence, it
is convenient to speak of a "binding protein" and its
"binding partner". The term "protein" is used herein in a
broad sense which includes, *mutatis mutandis*, polypeptides
and oligopeptides, and derivatives thereof, such as
15 glycoproteins, lipoproteins, and phosphoproteins, and
metalbproteins. The essential requirement is that the
"binding protein" feature one or more peptide (-NHCO-) bonds,
as the amide hydrogen of the peptide bond (as well as in the
side chains of certain amino acids) has certain properties
20 which lends itself to analysis by proton exchange.

The binding protein may be identical to a naturally
occurring protein, or it may be a binding fragment or other
mutant of such a protein. The fragment or mutant may have
the same or different binding characteristic relative to the
25 parental protein.

Integral membrane proteins are of particular interest,
as they are difficult to crystallize for study by X-ray
diffraction. Proteins too large to study by NMR methods,
e.g., those larger than about 50 kDa, are also of special
30 interest, particularly if they cannot be characterized as a
composite of two or more separately analyzable domains.
Examples of suitable proteins include integrins (which are
large integral membrane proteins), cell surface receptors for
growth factors (including cytokine receptors), "seven-
35 spanners", selectin, and cell surface receptors of the
immunoglobin superfamily (e.g., ICAM-1).

- 20 -

The method of the present invention is especially useful for studying proteins with discontinuous epitopes, such as certain antibodies, including certain clinically important autoimmune antibodies.

5   A "binding site" is a point of contact between a binding surface ("paratope") of the binding protein and a complementary surface ("epitope") of the binding partner. (When the binding partner is a protein, the designation of "paratope" and "epitope" is essentially arbitrary. However,

10 in the case of antibody-antigen interactions, it is conventional to refer to the antigen binding site of the antibody as the "paratope" and the target site on the antigen as the "epitope".) A specific binding pair may have more than one binding site, and the term "pair" is used loosely,

15 as the binding protein may bind two or more binding partners (as in the case of a divalent antibody). Moreover, other molecules, e.g., allosteric effectors, may alter the conformation of a member of the "pair" and thereby modulate the binding. The term "pair" is intended to encompass these

20 more complex interactions.

Slowed Hydrogen Exchange Conditions

The present invention contemplates labeling the binding site of a binding protein (or binding partner) with a heavy

25 hydrogen isotope, and determining the location of the labels under slowed hydrogen exchange conditions. "Slowed hydrogen exchange conditions" are hereby defined as conditions wherein the rate of exchange of normal hydrogen for heavy hydrogen at amide hydrogens freely exposed to solvent is reduced

30 substantially, i.e., enough to allow sufficient time to determine, by the methods described herein, the precise amide hydrogen positions which had been labeled with heavy hydrogen. The H-exchange rate is a function of temperature, pH and solvent. The rate is decreased three fold for each

35 10°C drop in temperature. Hence use of temperatures close to 0°C is preferred. In water, the minimum H-exchange rate is at a pH of 2-3. As conditions diverge from the optimum pH,

- 21 -

the H exchange rate increases, typically by 10-fold per pH
unit increase or decrease away from the minimum. Use of high
concentrations of a polar, organic cosolvent shifts the pH
min to higher pH, potentially as high as pH 6 and perhaps,
5 with the right solvent, even higher.

At pH 2.7 and 0°C., the typical half life of a tritium
label at an amide position freely exposed to solvent water is
about 70 minutes. Preferably, the slowed conditions of the
present inventions result in a half-life of at least 10
10 minutes, more preferably at least 60 minutes.

Tritium Exchange Embodiments

In one embodiment, the present invention contemplates
the following procedure for characterization of a binding
15 site or the high resolution identification of solvent-
accessible peptide amide groups:

A.   The phenomenon of hydrogen (tritium) exchange is
used to substitute a radioactive probe (tritium) for each of
the amide hydrogens on the amino acids which make up the
20 surface of the receptor protein, including the surface of the
receptor's ligand binding site. This labelling is
accomplished under essentially physiologic conditions by
incubating the receptor protein in solutions containing
tritiated water. (Preferably, the water is of high specific
25 activity.)

If one desires to characterize the binding site of the
protein, the following steps (B) and (C) are performed.

B.   Protein ligand (binding partner) is then added to
the on-exchanged (tritiated) receptor protein and allowed to
30 bind to its specific site on the receptor. Once the ligand
has bound to the receptor, hydrogens on the amino acids which
make up the surface of the receptor's binding site are no
longer capable of efficiently interacting with the
surrounding aqueous buffer, and further hydrogen exchange is
35 markedly inhibited.

C.   The tritiated receptor-ligand complex is then
transferred to physiologic buffers free of tritium. Tritium

- 22 -

label on the receptor-ligand complex is allowed to exchange
off the receptor. However, binding complex-dependent
hydrogen-bonding between the protein and binding partner and
limited solvent accessibility to the protein-binding partner
5 interface in the complex are selective impediments to the
off-exchange of peptide amide tritium label sandwiched
between the protein and binding partner. After the removal
(off-exchange) of tritium from other regions of the protein-
binding partner complex is substantially finished, the result
10 is the preferential retention of tritium label at the amides
for which hydrogen exchange is slowed by virtue of protein-
binding partner interactions, typically amides proximate to
amino acids which make up the surface of the receptor's
ligand binding site. Optionally, the complex may be
15 subjected to limited proteolytic digestion, denaturation
and/or disulfide reduction while off exchange is proceeding,
as long as the integrity of the binding protein: binding
partner interaction is not substantially perturbed by such
maneuvers.
20   Alternatively, the receptor ligand complex can be
tritiated such that the peptide amide groups which compose
the binding site and/or binding surface are not labeled and
all other solvent-accessible peptide amide groups are
selectively labeled. Thus, in this alternative embodiment,
25 peptide amide groups which comprise the binding site and/or
binding surfaces are "functionally labeled" by the absence of
tritium.
       D.   The specific peptide bond amides which bear tritium
are then identified. This is done by:
30   (1) shifting the labeled receptor-ligand complex to
       conditions (e.g., 0-4°C, pH 2.7) which dissociate the
       complex and at the same time slow down amide hydrogen
       exchange.
            (2) optionally subjecting the receptor to
35   proteolysis followed by reverse phase (RP) high pressure
       liquid chromatographic (HPLC) separation (preferably 2-
       dimensional) of the resulting receptor fragments under

- 23 -

continued slow proton exchange conditions. Receptor
fragments bearing tritium label are identified,
isolated, and characterized as to their amino acid
sequence, and therefore their location within the
5   primary amino acid sequence of the intact receptor.
Preparation of the binding protein for proteolytic
analysis may involve:
        (a)   trimming off of portions of the protein not
required for complex formation;
10   (b)   disruption of disulfide bonds which could
complicate the analysis of the fragments (see section 5A);
and/or
        (c)   denaturation of the protein to render it more
susceptible to proteolytic attack (see section 5B).
15   Step (a) may be performed before or after switching to
slow hydrogen exchange conditions, since it does not cause
dissociation of the contacting surfaces. Steps (b) and (c)
are more likely to cause such dissociation and therefore will
more often need to be performed under slow exchange
20 conditions.
        (3) determining the location of tritium label within the
binding protein or each labeled peptide fragment from step
(2) by subfragmenting the labeled binding protein or peptides
(e.g., with acid-reactive carboxypeptidases or tritium-
25 exchange-compatible chemical methods) under slow proton
exchange conditions and characterizing the labelled
subfragments. For example, the identity of each of the
subfragments may be determined by amino acid analysis,
peptide sequencing, or by comparison of their mobility with
30 synthetic HPLC mobility marker peptides, and the amount of
tritium label attached to each subfragment determined by
scintillation counting. As each carboxy-terminal amino acid
of the functionally labeled binding protein or peptide
fragment is sequentially cleaved off by the carboxypeptidase,
35 the nitrogen which formed the slowly-exchanging peptide amide
in the intact peptide bond is converted to a rapidly
exchanging secondary amine, and any tritium label at that

- 24 -

nitrogen is lost from the peptide within seconds, whereas all
other amide bond tritium remains in place. A stepdown in
radioactivity from one subfragment to the next smaller one
indicates that the amide just altered had been labeled with
5 tritium.

        In this manner, the precise location, within the
protein, of each peptide amide that is functionally labeled
by virtue of its solvent-accessibility and/or its interaction
with its binding partner is determined. Inferentially, in
10 this manner, the precise amino acids which make up the
surface of the receptor and/or the surface of the receptor's
binding site are then known. Studies may be performed to
quantify the exchange rates of each of the labeled amides
identified above both before and after complex formation with
15 binding partner. This allows calculation of the magnitude of
exchange slowing experienced by each of these amides
consequent to complex formation, and allows optimization of
on and off exchange times.

        E.   Parallel studies may be performed in which the
20 cognate binding partner is on-exchanged with tritium,
complexed with receptor protein, off-exchanged as a binding
partner-protein complex and slowed amides in the binding
partner identified as above. This procedure results in the
identification of the subregions of the binding partner which
25 interact with the protein.

        F.   The knowledge of the identity of the precise
contact peptides in both receptor and ligand may be combined
with additional structural information provided by the
invention (identification of peptide amides of the protein
30 and binding partner which are likely to directly form
hydrogen bonds between protein and binding partner upon
complex formation) to produce models for the complementary 3-
dimensional structures of the receptor and ligand interaction
surfaces. These models may then be used as the basis of the
35 design and production of appropriate peptide and
peptidomimetic drugs.

The individual steps of this procedure will now be considered in greater detail.

1. On-Exchange

5   The protein under study is incubated in buffer supplemented with tritiated water (^3H_2O), preferably of high specific activity. This results in the time dependent reversible incorporation of tritium label into every peptide amide on the surface of the protein, including its
10   (potential) ligand binding subregion, through the mechanism of proton exchange.

Any physiologic buffer appropriate for the interaction of the protein with its binding partner may be utilized (with no constraints imposed on buffer pH or temperature).
15   Suitable buffers include phosphate buffered saline (PBS), 0.15 mM NaCl, 10 mM PO_4, pH 7.4 PBS. The use of small incubation volumes (0.1-10 μl) containing high concentrations of receptor protein (10-100 mg/ml) is preferred.

The necessary level of tritiation (and hence the
20   concentration of tritium in the buffer) is dependent on the total amount of protein available for analysis. For analysis of 1mg protein, at least 10 Ci/ml is desirable; for 0.1mg, 100 Ci/ml, and for .01mg, 1000 Ci/ml. (Pure tritiated H_2O is about 2500 Ci/ml.) For most applications, the tritiated
25   water will be 50-500 Ci/ml. Without the use of these high specific activities, studies of proteins which are available in limited quantity would be much more difficult. (Even higher specific activity (e.g., 500-1,500 Ci/ml) may be used in the invention, but radiation safety considerations
30   necessitate performance of such on- and off-exchange procedures in specialized facilities, such as are available in the tritium laboratory provided by the National Tritium Facility, Lawrence Berkeley Laboratories, University of California, Berkeley.)
35   It should be noted that with customary levels of tritium, only a small percentage of the binding protein molecules will be tritiated at any given exposed position.

- 26 -

All that is required is that substantially each of the
exposed amide hydrogen atoms be replaced in a detectable (by
radiation counting) number of the binding protein molecules.

   It is not necessary that the tritium exchange analysis
5 rely on only a single choice of "on-exchange" time. Rather,
the skilled worker may carry out the experiment using a range
of on-exchange times, preferably spanning several orders of
magnitude (seconds to days) to allow selection of on-exchange
times which allow efficient labeling of the various peptide
10 amides present in the protein, which will become slowed in
their exchange rate consequent to the interaction of the
protein to its binding partner, and at the same time minimize
background labeling of other amide positions after off-
exchange is completed (see section 10 below).
15

   2.   *Receptor-Binding Partner Complex Formation*
   After a suitable period of tritium on-exchange, the
protein's binding partner is added to the tritiated protein-
buffer solution and the two allowed to form a binding
20 complex. The binding partner is preferably added in
quantities sufficient to produce saturation binding to the
protein (usually equimolar amounts) and at high
concentrations (e.g., 10-100 mg/ml) to maximize the rate and
extent of binding. To minimize tritium labeling of the added
25 binding partner by proton exchange (important when utilizing
short on-exchange times), ^3H_2O in the buffer is preferably
diluted with tritium-free buffer (10-1000 fold dilution)
within 0-100 seconds of binding partner addition. Additional
manipulations detailed below may be used at this step to
30 further minimize incorporation of tritium label into the
binding partner.

   3.   *Off-Exchange*
   The tritiated protein-binding partner complex is then
35 transferred to physiologic buffers identical to those
employed during on-exchange, but which are substantially free
of tritium. Tritium label on the protein then exchanges off

- 27 -

the protein at rates identical to its on-exchange rate
everywhere except at amides which have been slowed in their
exchange rate by virtue of the interaction of protein with
binding partner. With sufficient off-exchange time, the
5 result is the specific retention of tritium label at each of
the peptide amide bonds which occur between the amino acids
which make up the surface of the protein's binding site for
the binding partner. We refer to this process as a complex
formation-dependent functional labeling of the protein with
10 tritium. At least 90%, more preferably, at least 95%, 96%,
97%, 98% or 99% or more, of on-exchanged tritium label at
other sites is off-exchanged from the protein.

        In general, off-exchange is allowed to proceed for 5 to
50 times, more preferably about 10 times longer than the on-
15 exchange period, as this allows off-exchange from the protein
of greater than 99% of the on-exchanged tritium label which
has not experienced a slowing of exchange rate subsequent to
the protein's interaction with binding partner. Preliminary
studies may be performed with the protein and binding partner
20 to determine the on and off exchange times which optimize the
signal (tritium remaining in functionally labeled amides) to
noise (tritium remaining in background amides) ratio (see
section 8).

        In preferred embodiments, the off-exchange procedure may
25 be performed with the use of Sephadex G-25 spin columns
prepared and utilized as described in Example 1 (below), by
G-25 column chromatography as described by Englander (6,19)
or by use of perfusive HPLC supports that allow rapid
separation of peptide/protein from solvent (Poros® columns,
30 PerSeptive Biosystems, Boston, MA). Use of the G-25 spin
columns allows the separation of the complex from greater
than 99.9% of buffer tritium. Residual buffer tritium and
tritium off-exchanged from the complex may optionally be
further removed by dialysis of the complex against tritium
35 free buffer during off exchange.

        Alternatively, complex formation and off-exchange can be
accomplished by first reacting the on-exchanged protein-

                                - 28 -

buffer mixture with binding partner which has been covalently
attached to a solid support (e.g. binding-partner-Sepharose),
allowing the on-exchanged protein to complex to the solid-
phase binding partner, followed by washing of the sepharose-
5 binding partner-protein conjugate with tritium free buffer.
Alternatively, soluble protein-binding partner complexes may
be formed as above, and captured with a solid phase adsorbent
that can bind to either the protein or binding partner
component of the complex (e.g. Sepharose with covalently
10 attached antibodies specific for protein or binding partner).

Most protein-ligand binding interactions that will be
probed with this technique are reversible reactions: binding
partner will dissociate from and rebind to the protein during
the off-exchange period, and during the brief intervals where
15 the protein's binding site is unoccupied with binding
partner, proton off-exchange proceeds at the unprotected
rate. It is therefore important to minimize the time that
the binding site is unoccupied. In a preferred embodiment,
this is accomplished by having both receptor and binding
20 partner present at high concentration, e.g., at least mg/ml
concentrations, up to 100 mg/ml concentrations each
throughout the off-exchange period, and performing the on and
off exchange reactions at temperatures at or below room
temperature, preferably 4°C.
25
    4. Trimming of the Binding Protein (optional)
        Prior to dissociation of the complex, e.g., during the
off-exchange period, which typically lasts hours to days, the
complex may optionally be chemically or enzymatically treated
30 to produce the smallest fragment of protein which is still
capable of remaining tightly bound to the binding partner,
and this residual "trimmed" complex isolated. Removal of
portions of the protein not essential for continued complex
formation will decrease the number of background peptides
35 generated during the subsequent acid proteolysis of the
trimmed complex (Section 6). This pre-digestion and
purification can be performed with a wide variety of

- 29 -

proteases (e.g. trypsin, pronase, V-8 protease chymotrypsin
proteinase-K) as well as certain chemical agents (e.g.,
cyanogen bromide, iodosobenzoic acid), and under virtually
any conditions of induced partial protein denaturation (e.g.
5 urea, guanidinium chloride sodium dodecyl sulfate, non-ionic
detergents, reductants such as 2-mercaptoethanol,
dithiothreitol), ionic strength, temperature, time and pH
which do not substantially dissociate the contacting surfaces
of the protein-binding partner complex. Excessive digestion
10 efforts which result in dissociation of these surfaces from
each other will cause a large fraction of functional tritium
label to be immediately off-exchanged, as greater than 50% of
peptide amides in the dissociating surfaces will have
exchange half-lives of less than 1 minute at approximately
15 pH 7. The goal is to generate and isolate a fragment of the
protein, preferably 15-100 kD in size more preferably 15 kD,
which remains attached to the binding partner. Often "ligand
stabilization" of proteins which are proteolysed while bound
to binding partner allows the continued binding of the
20 protein fragments to partner.
        Preliminary studies may be performed with the off-
exchanged complex to determine conditions which result in a
suitably trimmed protein-binding partner complex. In a
preferred embodiment, the quantity of residual tritium
25 functionally bound to the intact off-exchanged complex is
first determined by measurement of tritium which migrates
with the void volume (Mr >10,000 kD) on a G-25 spin column
(pH 7.4). Aliquots of the complex are then subjected to
varied fragmentation conditions, and the fraction of tritium
30 label which remains attached to polypeptides under each
digestion condition (migrates with G-25 void volume)
determined. The proteolytic products of the most vigorous
digestions which "release" less than 5% of complex-associated
tritium are (as per Section 5) adjusted to pH 2.7, 0°C,
35 subjected to RP-HPLC at pH 2.7, 0°C, and peptides/protein
fragments which bear label identified, isolated, and their
molecular weights determined by SDS-PAGE. The labeled

- 30 -

proteolytic products produced in these limited digests are
likely to be large polypeptides, and therefore RP-HPLC
supports suitable to the purification of such peptides (C-4,
phenyl columns) are utilized. Alternatively, when solid-
5 phase adsorbents are used for complex formation/off-exchange
(step 3), proteolysis as above, now of the solid phase
binding partner-protein complex, is allowed to proceed as
extensively as possible without release from the solid
support of greater than 5% functionally attached tritium.
10 The predigested protein/complex is then released from the
immunoadsorbent with denaturants including a shift to pH 2.7,
and the predigested protein further proteolysed with pepsin
other acid reactive proteases.
         A binding protein may also be trimmed earlier, e.g.,
15 before "on-exchange" or before complex formation, provided
that the trimmed protein binds the partner sufficiently
similarly to the original protein to be of interest.

    5.   _Switch to Slow Amide Hydrogen Exchange Conditions_
20   The protein-binding partner complex (or predigested
complex--see Step 4) or selectively labeled protein in the
case of alternative embodiments of the invention wherein the
positions of solvent accessible peptide amide protons are to
be determined in the absence of a binding partner, is then
25 shifted to conditions of temperature and pH which greatly
slow the half life of peptide amide hydrogen exchange, and
essentially "freeze" in place the tritium labels. In a
preferred embodiment, the complex is shifted to 0°C, and pH
2.7 conditions under which the half life of exchange of
30 peptide amide label in fully denatured peptides is at least
70 minutes. The label will be sufficiently held in place
under these conditions so that several rounds of proteolytic
fragmentation, HPLC separation, and tritium quantification
can be performed without unacceptable loss of label.
35   For some binding proteins, switching to slow hydrogen
exchange conditions is sufficient to cause dissociation of

                              - 31 -

the complex. If not, a dissociating agent, such as a
chaotropic agent may be added.

5A. <u>Disruption of Disulfide Bonds</u> (optional)

5   High resolution localization of tritium label-bearing
amides requires the proteolytic generation of peptides less
than approximately 15-20 amino acids in size under conditions
which allow the label to remain in place (e.g., 0°C, pH 2.7).
The ability of any protease to fragment a protein or peptide
10   is limited by the accessibility of the protease to
susceptible peptide bonds. While denaturants such as acidic
pH, urea, detergents, and organic co-solvents can partially
denature proteins and expose many otherwise structurally
shielded peptide bonds, pre-existing disulfide bonds within a
15   protein can prevent sufficient denaturation with these agents
alone. In conventional protein structural studies,
disulfides are usually cleaved by reduction with 2-
mercaptoethanol, dithiothreitol, and other reductants which
unfortunately require a pH greater than 6 and elevated
20   temperature for sufficient activity, and are therefore not
useful for the reduction of disulfides at pH 2.7 or below.
For this reason, the tritium exchange art has not attempted
any form of disulfide bond disruption, has for the most part
been restricted to the study of proteins without intrinsic
25   disulfide bonds, and has accepted the low resolution
achievable without disulfide bond disruption. The applicant
has recognized and demonstrated that acid-reactive phosphines
such as Tris (2-carboxyethyl) phosphine (TCEP) (31-36) can be
used to disrupt disulfides under the acidic pH and low
30   temperature constraints required for tritium exchange
analysis (see FIGS. 7a-e). These manipulations disrupt these
associations and at the same time continue to produce a
markedly slowed proton exchange rate for peptide amide
protons.

35

5B.   Protein Denaturation. (optional)

In previous studies by Englander et al. and others,
employing medium resolution tritium exchange, proteolytic
fragmentation of tritium-labelled proteins under slowed-
5 exchange conditions was accomplished by shifting the
protein's pH to 2.7, adding high concentrations of liquid
phase pepsin, followed by brief (10 min.) incubation at 0°C.
With the proteins studied by Englander et al. simply shifting
pH from that of physiologic (7.0) to 2.7 was sufficient to
10 render them sufficiently denatured as to be susceptible to
pepsin proteolysis at 0°C. Furthermore, these proteins, in
general, did not contain disulfide bonds that interfered with
effective denaturation by such (acid) pH conditions or
contain disulfide bonds within portions of the protein under
15 study with the technique. The applicant has found that other
proteins (for example hen egg lysozyme) are negligibly
denatured and are not substantially susceptible to pepsin
proteolysis when continuously incubated at comparable acidic
pH and depressed temperature (10-0°C). This is the
20 consequence of the existence of a thermal barrier to
denaturation for many proteins incubated in many denaturants;
i.e., denaturation of proteins at lower temperatures (10-0°C)
is often inefficient and a slow process, incompatible with
the requirement of medium resolution tritium exchange
25 techniques that manipulations be performed rapidly, such that
the attached tritium label is substantially retained at
functionally labelled amides of the binding protein.

The applicant has discovered that such proteins become
extraordinarily susceptible to pepsin proteolysis at 0°C when
30 they are treated with the sequential denaturation procedure
described below. Furthermore, the applicant has discovered
that although TCEP can effect the reduction of disulfide
bonds in proteins at 0°C and pHs in the range of 2-3, it is
relatively inefficient at doing so under these conditions and
35 becomes much more efficient at effecting reduction at a pH of
5.0 or greater. Conditions can be arranged to greatly
increase the efficiency of TCEP-mediated reduction while at

- 33 -

the same time preserving slow exchange conditions. This is
accomplished by simultaneously denaturing the protein with
guanidine thiocyanate, employing very high concentrations of
TCEP and raising the pH of the solution to 5.0. While this
5 pH would normally produces an unacceptable 100-fold increase
(as compared to that at pH 2.7) in the rate of loss of
tritium from the labelled protein, the elevated pH-induced
increase in the rate of tritium loss is substantially offset
by limiting the water content of the incubation mixture (and
10 thereby markedly slowing the rate of tritium loss) when the
protein is being reduced at pH 5.0, and the solution pH then
is shifted back to pH 2.7 once reduction is complete. The
result is effective reduction of proteins at a pH of 5 and
0°C with substantially complete retention of tritium label on
15 the binding protein.

The denatured (or denatured and reduced) protein
solution is then passed over a pepsin-agarose column,
resulting in efficient and rapid fragmentation of the protein
(in ≤ 1 min.). The fragments can be, and usually are,
20 immediately analyzed on RP-HPLC without unnecessary
contamination of the peptide mixture with the enzyme pepsin
or fragments of the enzyme pepsin. Such contamination is
problematic with the technique as taught by Englander, et
al., as high concentrations of pepsin (often equal in mass to
25 the protein under study) are employed, to force the
proteolysis to occur sufficiently rapidly at 0°C.

While proteins are often subjected to purposeful
denaturation with agents other than a pH shift prior to
digestion with pepsin, this has never been done at depressed
30 temperatures (10- 0°C) before, and the applicant has
discovered that while guanidine thiocyanate at the indicated
concentrations is sufficient to suitably denature and render
susceptible to pepsin proteolysis proteins at 10-0°C, several
other strong denaturants, including urea, HCl, sodium dodecyl
35 sulfate (SDS) and guanidine HCl, were, at least when used
alone, unable to adequately denature lysozyme at these low
temperatures. However, the concentrations of guanidine

- 34 -

thiocyanate required for such denaturation are incompatible with pepsin digestion; i.e., they denature the pepsin enzyme before it can act on the denatured binding protein. When the guanidine thiocyanate is removed (at 10-0°C) from the
5   solution after protein denaturation has been accomplished in an attempt to overcome this inhibition of pepsin activity,, the protein rapidly refolds and/or aggregates, which renders it again refractory to the proteolytic action of pepsin.

The applicant has discovered that if proteins are first
10 denatured in ≥ 2M guanidine thiocyanate at 0°C and the concentration of thiocyanate then reduced to ≤ 2M while at the same time the guanidine ion is maintained ≥ 2M (by diluting the guanidine thiocyanate into guanidine hydrochloride), the denatured protein remains in solution,
15 remains denatured, and the enzyme pepsin is efficiently proteolytically active against the denatured protein in this solution at 0°C. The stability of pepsin-agarose to this digestion buffer is such that no detectible degradation in the performance of the pepsin column employed by the
20 applicant has occurred after being used to proteolyze more than 500 samples over 1 years. No pepsin autodigestion takes place under these conditions.

Denaturation without concomitant reduction of the binding protein may be accomplished by contacting it (at
25 0-5°C) with a solution containing ≥2 molar guanidine thiocyanate pH 2.7, followed by the addition of an equal volume of 4 molar guanidine hydrochloride pH 2.7.

Denaturation with disulfide reduction may be accomplished by contacting the binding protein with a
30 solution containing ≥2 molar guanidine thiocyanate, 0.3-0.7 molar TCEP, 5-20% H_2O (by volume), with the balance of volume being acetonitrile, dimethyl sulfoxide, or other water miscible nonaqueous solvent in which the denaturant (e.g. guanidine thiocyanate) and disulfide bond disrupting agent
35 (e.g., TCEP), if used, remain soluble at substantially these concentrations, and such that the solvent system does not freeze at the "slow exchange" temperature. The pH of the

- 35 -

solution is preferably in the range of 4.8-5.2, optimally
5.0.   After this incubation, 2 volumes of a 2.5 molar
guanidine hydrochloride solution is added, with the pH and
buffering capacity of the solution such as to achieve a pH of
5 2.7 in the final mixture.

Denatured (with or without reduction) binding protein is
then passed over a column composed of insoluble (solid state)
pepsin, whereby during the course of the passage of such
denatured or denatured and reduced binding protein through
10 the column, it is substantially completely fragmented by the
pepsin to peptides of size range 1-20 amino acids at 0°C and
at pH 2.7.   The effluent from this column (containing
proteolytically-generated fragments of binding protein) is
directly and immediately applied to the chromatographic
15 procedure employed to separate and isolate protein fragments,
preferably analytical reverse-phase HPLC chromatography.

It should be noted that denaturants, besides rendering
the binding protein more susceptible to proteolysis, also
help dissociate it from its partner.
20

6.   *Generation of Peptide Fragments* (Optional)
To ultimately localize the protein's amides which are
functionally labeled with tritium, small peptides bearing the
retained tritium label (preferably, 5-25 amino acids in size)
25 are optionally proteolytically generated from labeled protein
and separated from the many other unlabeled peptides
generated by fragmentation of the protein, all under
conditions which minimize off-exchange of amide tritium from
the peptide.   Small peptides have little secondary structure
30 and therefore their amides are free to exchange with solvent
hydrogen.   If tritium label is to remain in place on such
peptides, proteolysis and purification (e.g., RP-HPLC)
conditions must be adjusted to slow such off-exchange.

The labeled and dissociated binding protein is therefore
35 fragmented under slow H-exchange conditions, e.g., by
proteolysis with high concentrations of a protease which is
stable and active with the aforementioned conditions (e.g.,

- 36 -

pH 2.7, 0°C). Suitable acid tolerant proteases include
pepsin (19), cathepsin-D (37) *Aspergillus* proteases (37a-
37c), thermolysin (38) and mixtures of these proteases. In a
preferred embodiment, pepsin is used, preferably at a
5 concentration of 10 mg/ml pepsin at 0°C pH 2.7 for 5-30
minutes, preferably 10 minutes.

        Other physical and chemical fragmentation methods may be
used provided they are (1) are compatible with slow H-
exchange conditions, (2) do not cause shifts in the positions
10 of the amide labels, and (3) produce a reasonable number of
fragments from the protein of interest.

        Preferably, prior to fragmentation of the binding
protein, binding partner (if susceptible to the fragmenting
agent) is removed, so as not to complicate purification with
15 binding partner fragments.

6A.   Purification of Fragments

        As acid proteases in general have very broad cleavage
specificity, they fragment the protein into a very large
20 number of different peptides. In most protein-binding
partner systems studied by tritium exchange, it is likely
that the interacting binding surfaces will contain roughly
10-20 tritium labeled peptide amide which upon proteolysis
will result in approximately 1-5 label-bearing peptides, the
25 precise number depending on the inherent fragmentation mode
of the protein under study with the proteases utilized. The
number of "background," non-labeled peptides (derived from
regions of the protein and binding partner that do not
participate in the binding interaction) generated by the
30 fragmentation procedure will be a direct function of the size
of the protein. Background peptides will be present in the
proteolytic digest in numbers 10-1,000 times greater than
will be functionally labeled peptides when proteins with
sizes in the range of 30-200 kD are proteolyzed.
35   This large number of background peptides causes two
difficulties: First, they must all be cleanly separated from
the functionally labeled peptides to allow identification of

                                - 37 -

the label-bearing peptides. Second, background peptides
contain small amounts of tritium label and even though the
amount of label per background peptide is generally less than
1% of that of functionally labeled peptides, background
5 peptides are present in much greater amounts and are likely
to obscure the presence of functionally labeled peptides and
analytical separation.

Given these considerations, only proteins less than 30
kD in size have been successfully characterized in the past
10 by medium resolution tritium exchange. Upon acid proteolysis
of larger proteins, so many different fragments would be
obtained that individual fractions obtained on a single HPLC
separation performed at pH 2.7 would be unacceptably
contaminated with background peptides.

15   Any method of purifying the fragments which is capable
of resolving the mixture while maintaining slow H exchange
condition is acceptable. The preferred method is high
pressure liquid chromatography (HPLC), especially in reverse
phase (RP). (An alternative method is that of mass
20 spectroscopy.)

The art has overstated the sensitivity of the tritium
label to pH. Englander (10) reported that at 0°C., the
tritium label was most stable (when the tritiated protein was
placed in an untritiated aqueous buffer) at pH 2.7, and that
25 the rate of off-exchanged increased rapidly (10 fold per pH
unit) as one moved away from that pH. Surprisingly,
Applicant found that at 0°C., the label was sufficiently
stable to permit analysis even at a pH of 2.1. While the
acceptable pH range will vary with temperature, and the
30 choice of solvent (the optimal pH increases if a polar
nonaqueous solvent is introduced), the fact remains that pH
was previously considered to be essentially fixed. Since the
tritium label is stable over a broader pH range, such as 2.1-
3.5, it is possible to depart from Englander's recommended pH
35 of 2.7 in seeking HPLC conditions which result in effective
separation of the peptide fragments.

- 38 -

When the binding molecules are large, so many different
fragments are obtained after proleolytic digest that some of
the individual peaks on a single HPLC separation, even at
optimized ph, may be heterogeneous.

5   RP-HPLC resolution of co-migrating multiple peptides may
be greatly improved by resorting to a two-dimensional RP-HPLC
separation in which two sequential RP-HPLC separations are
performed at substantially different pH's, e.g. 2.7 and 2.1.

A two-dimensional HPLC separation allows high efficiency
10 purification of tritium label bearing-peptides from the
enormous number of unlabeled peptides generated by peptic
fragmentation of large proteins. Two-dimensional separation
of molecules is known in the chromatographic art. However,
despite frequent complaints in the Tritium exchange
15 literature about resolution problems, 2D separations have not
been employed previously in connection with Tritium exchange.

In a preferred embodiment of the invention, tritium-
labeled protein fragments are first separated by means
capable of sufficiently resolving the fragments, such as by
20 RP-HPLC (utilizing any of a number of potential
chromatographic support including C4, C18, phenol and ion
exchange, preferably C18). This separation may be performed
at pH 2.1-3.5 and at 4-0°C, more preferably, at pH 2.7 and
0°C, which may accomplished by employment of any buffer
25 systems which operate at this pH, including citrate,
chloride, acetate, more preferably phosphate. Peptides are
eluted from the reverse phase column with a similarly
buffered gradient of polar co-solvents including methanol,
dioxane, propanol, more preferably acetonitrile. Eluted
30 peptides are detected by on-line ultraviolet light absorption
spectroscopy performed at frequencies between 200 and 300 nm,
preferably 214 nm. Tritium label is detected by
scintillation counting of a sampled fraction of the HPLC
column affluent. Peptides bearing label that has been
35 specifically protected from off-exchange by complex formation
with binding partner are identified by comparing the specific
activity of each labeled peptide to the specific activity of

the same peptide prepared from protein subjected to identical
on/off exchange, proteolysis and HPLC conditions, but which
have been off-exchanged without added binding partner.

    HPLC fractions containing peptides with such

5 functionally labeled amides are then subjected to a second
dimension RP-HPLC separation which may be performed at pH
2.1-3.5 and 4-0°C, more preferably, at pH 2.1 and 0°C,
accompanied by any buffer systems which operates at this pH,
including citrate, chloride, acetate, phosphate, more

10 preferably TFA (0.1-0.115%). Peptides are eluted from their
reverse phase column with a similarly buffered gradient of
polar co-solvents including methanol, dioxane, propanol, more
preferably acetonitrile. Eluted peptides are detected,
tritium measured and functionally labeled peptides identified

15 as in the first HPLC dimension described above. Functionally
labeled peptides are isolated (collection of the appropriate
fraction of column effluent), water, acetonitrile, and TFA
removed by evaporation, and the remaining purified peptides
each characterized as to its primary amino acid structure by

20 conventional techniques, e.g., amino acid analysis of
complete acid hydrolysates or gas-phase Edman degradation
microsequencing. Reference is then made to the previously
known amino acid sequence of the intact protein to infer the
location of the tritium-labeled peptides within the intact

25 protein's primary sequence. Employment of TFA buffer in the
second dimension has the additional advantage that no
residual salt (i.e. phosphate) remains after solvent
evaporation. Residual phosphate frequently interferes with
the chemical reactions required for amino acid analysis and

30 Edman degradation, a problem obviated by the use of volatile
TFA in the second dimension buffer.

    Most preferably, proteolytic digests are first separated
at pH 2.7 in phosphate buffered solvents and each eluted
peptide peak fraction which contains tritium-labeled amides

35 is identified, collected, and then subjected to a second HPLC
separation performed in trifluoracidic acid (TFA)-buffered
solvents at pH 2.1.

- 40 -

7.   *High Resolution Sublocalization of Labeled Amides*
     Within Label-Bearing Peptides.

To routinely localize peptide amide tritium label to the
single amino acid level, applicant systematically cleaves
5 every peptide bond within the labeled protein or a purified
label-bearing peptide fragment. Slow H-exchange conditions
must be used for this proteolysis as the small peptides
generated have no stable conformational structure and rapid
loss of tritium label from the amides would occur if rates of
10 exchange were not slowed, e.g., by ambient acidic pH.

Most known acid-reactive proteases cleave peptides in a
basically nonspecific manner similar to that of pepsin;
studies employing other pepsin-like proteases have not proved
to be of significant utility in increasing resolution of
15 labeled amides.

A special class of acid-reactive proteases, the
carboxypeptidases, are able to generate all required
subfragments of labeled protein or pepsin-generated peptides
in quantities sufficient for high resolution tritium
20 localization. Many carboxypeptidases are active at pH 2.7
and sequentially cleave amino acids from the carboxy terminus
of peptides. Such enzymes include carboxypeptidase P, Y, W,
and C (39). While carboxypeptidases have been used for
limited carboxy-terminal sequencing of peptides, often at pH
25 in the range of 2.7 (40), their use in tritium exchange
techniques has not been disclosed. The need to minimize
tritium losses forbids the use of carboxypeptidases which are
inactive in acidic (pH 2.7) buffers, such as
carboxypeptidases A and B. However, carboxypeptidase-P, Y,
30 and several other acid-reactive carboxypeptidases (W,C) are
suitable for proteolysis of peptides under acidic conditions
(39). The tritium exchange art has failed to recognize the
utility of carboxypeptidases to tritium exchange studies,
possibly because the carboxypeptidases are even more
35 nonspecific in the types of peptide bonds they cleave than
are pepsin-like proteases and therefore might have been

- 41 -

thought to result in inadequate recovery of any single
subfragment.

Furthermore, chemical procedures employing
pentafluoropropionic anhydride can produce sets of C-
5 terminal-truncated peptide fragments under slowed amide
exchange conditions (see below, 41,42).

In the preferred embodiment, tritium-exchange-labeled
proteins are nonspecifically fragmented with pepsin or
pepsin-like proteases, the resulting tritium-labeled peptides
10 isolated by two-dimensional HPLC and these in turn
exhaustively subfragmented by controlled, step-wise digestion
with acid-(i.e., enzymatically active under acidic
conditions) exopeptidases and/or by chemical means (see
below). These digests are then analyzed on RP-HPLC performed
15 at 0°C in TFA-containing buffers (pH 2.1) and each of the
generated subfragments (typically 5-20) is then identified.
The identity of each of the several subfragments maybe
determined by any suitable amino acid analysis, peptide
sequencing, or through the use of synthetic HPLC mobility
20 marker peptides, and the amount of tritium label attached to
each subfragment truncated peptide determined by
scintillation counting. In this manner, the precise
location, within the protein, of each peptide amide that is
functionally labeled with tritium by virtue of its
25 interaction with binding partner is determined. By
consideration of the tritium content of each of the
identified subfragments the amide hydrogens which had been
replaced by tritium during the "on-exchange" step may be
inferred. It should be noted that the purpose of the
30 carboxypeptidase treatment is to generate the subfragments;
the method does not require use of carboxypeptidase to
sequence the fragments or subfragments. Preferably, the
sequence of the binding protein, or at least of the material
portion thereof, is known prior to commencement of the
35 present method. However, it may be determined at any time,
even after the subfragmentation, although the data gleaned

from the subfragmentations cannot be properly interpreted
until the sequences of a least the source is known.

Controlled sequential carboxy-terminal digestion of
tritium-labeled peptides with carboxypeptidases can be
5 performed under conditions which result in the production of
analytically sufficient quantities of a set of carboxy-
terminal truncated daughter peptides each shorter than the
preceding one by from one to about 5 carboxy-terminal amino
acid residues, preferably by a single carboxy-terminal amino
10 acid. As each carboxy-terminal amino acid of the
functionally labeled peptide is sequentially cleaved by the
carboxypeptidase, the nitrogen which formed the slow-
exchanging peptide amide in the intact peptide bond is
converted to a rapidly exchanging secondary amine, and any
15 tritium label at that nitrogen is lost from the peptide
within seconds, even at acidic pH. A difference in the molar
quantity of tritium label associated with any two sequential
subpeptides implies that label is localized at the peptide
bond amide which differs between the two subpeptides.
20   In a preferred embodiment, synthetic peptides are
produced (by standard peptide synthesis techniques) that are
identical in primary amino acid sequence to each of the
functionally labeled pepsin-generated peptides identified in
Step 6. The synthetic peptides may then be used in
25 preliminary carboxypeptidase digestion (pH 2.7, 0°C) and HPLC
(in TFA-buffered solvents) studies to determine; 1) the
optimal conditions of digestion time and protease
concentration which result in the production and
identification digestion on all possible carboxypeptidase
30 products of the peptide under study; and 2) the HPLC elution
position (mobility) of each carboxypeptidase-generated
subfragment of synthetic peptide.

To facilitate this latter procedure, a set of reference
peptides may be produced consisting of all possible carboxy-
35 terminal truncated daughter peptides which an acid
carboxypeptidase could produce upon digestion of a "parent"
peptide. These serve as HPLC mobility identity standards and

- 43 -

allow the deduction of the identity of daughter peptides
actually generated by carboxypeptidase digestion. Certain
daughter peptides may be enzymatically produced in quantities
insufficient for direct amino acid analysis or sequencing,
5 but their HPLC mobility can be measured and compared to that
of the synthetic peptides. Peptides can be detected and
quantified by standard in-line spectrophotometers (typically
UV absorbance at 200-214 nM) at levels well below the amounts
needed for amino acid analysis or gas-phase Edman sequencing.
10   After these preliminary studies, the pepsin-generated
HPLC isolated, functionally labeled peptide (prepared in Step
6) is then carboxypeptidase digested and analyzed under the
foregoing experimentally optimized conditions, the identity
of each fragment determined (by peptide sequencing or by
15 reference to the mobility of reference peptide mobility
marker) and the amount of tritium associated with each
peptide subfragment determined.
        Alternatively, a chemical technique may be used for the
successive carboxy terminal degradation of peptides under
20 slowed tritium exchange conditions. Tritium-labeled peptides
in HPLC buffers are held at -35°C and solvents removed by
cryosublimation (40a, 40b; vacuum at 1-20 millitorr, solvents
collected in a liquid nitrogen trap). The dried peptide is
then reacted with vapor phase pentafluoropropionic acid
25 anhydride (PFPA) as described in (54,55) except that the
peptide temperature is kept at -35°C for times up to 3 hours.
PFPA is then removed by vacuum and the fragmented peptide
made to 50 mM PO_4 pH 2.7, and analyzed by HPLC.
        In general, the known aminopeptidases are not able to
30 sequentially degrade a peptide under slow hydrogen exchange
conditions. However, if an acid-reactive aminopeptidase is
discovered in nature, or produced by mutation of a known
aminopeptidase, there is no reason that an aminopeptidase can
not be used in place of the presently preferred
35 carboxypeptidase. In that event, the stepwise degradation
will begin at the N-terminal, rather than the c-terminal, of
each analyzed peptide fragment.

- 44 -

It should be noted that by using polar, nonaqueous high
concentrations of cosolvents to shift the pH_{min} of the H-
exchange rate, a greater variety of reagents may be used than
would otherwise be the case. A cosolvent of particular
5 interest in this regard is glycerol (or other polyols), as it
is unlikely to denature the enzyme when employed at the high
concentration to substantially shift the pH min.

8.   *Optimization of on and off exchange times*.
10   Each peptide amide hydrogen associated with the protein-
binding partner interaction surface has a unique exchange
rate with solvent tritium in the native folded, unliganded
state, which is then shifted to another distinct exchange
rate once protein-binding partner complex formation has
15 occurred. The signal to noise ratio (ratio of tritium
functionally bound to this peptide amide over total
background tritium bound to all other peptide amides in the
protein) can be optimized by a knowledge of the exchange
rates of this amide hydrogen in the native unliganded protein
20 and in the protein-binding partner complex.
        An amide hydrogen with an exchange half-life of one
minute in the protein's native, unliganded state and 10
minutes in the liganded state might be optimally studied by
on-exchanging the receptor protein for 2 minutes (2 half-
25 lives of on-exchange time will result in incorporation of
tritium at 75% of the maximal possible equilibrium labeling
of the peptide amide) followed by 10 minutes of off-exchange
in the liganded state (50% of on-exchanged label will remain
on the functionally labeled peptide amide and less than 0.1%
30 of on-exchanged label will remain on each of the background
labeled peptide amides).
        To measure the exchange rates of a particular
functionally labelable peptide amide as it exists in the
native, unliganded protein, aliquots of protein are on-
35 exchanged for varying times (0.5 seconds to 24 hours), bound
to binding partner, and then off-exchanged for a fixed time,
preferably 24 hours. After pH 2.7, 0°C proteolytic digestion

and HPLC separation, radioactivity associated with the
peptide fragment containing the peptide amide under study is
measured. The amount of the radioactivity which represents
background (amides which are not functionally labeled) is
5 determined by measuring the amount of label associated with
the same peptide when the protein is on-exchanged for the
same duration but off-exchanged for 24 hours in the absence
of added ligand prior to proteolysis and HPLC analysis.
Specific radioactivity associated with the amide is
10 determined as a function of on-exchange time, and the half-
life of (on) exchange of the amide in the unliganded protein
calculated.

To determine the exchange rate of the same peptide amide
when it is in the protein-binding partner complex, protein is
15 on-exchanged for a fixed, long period of time (preferably 24
hrs) complexed with binding partner, off-exchanged for
varying times (preferably 10 seconds to 4 days), acid
proteolysed, and HPLC analyzed as above. Specific
radioactivity associated with the amide is determined as a
20 function of off-exchange time, and the half-life of (off)-
exchange of the amide in the liganded protein calculated.
With this information the times of on and off-exchange are
adjusted to optimize the signal/noise ratio for each of the
amides functionally labeled in the protein-binding partner
25 system under study.

9.   _Modeling of Receptor-Ligand Contact Surfaces_.
Studies identical in design to those described above (1-
8), may also be performed on the corresponding binding partner
30 protein (the binding partner protein is on-exchanged,
liganded to receptor protein, off-exchanged, etc.), resulting
in the identification of the amides of the binding partner
which are slowed in exchange by virtue of interaction with
receptor protein. The knowledge of the identity of the
35 precise contact peptides in both protein and binding partner
may be used to produce computer-assisted models for the

- 46 -

complementary 3-dimensional structures of the protein and
binding partner surfaces.

Construction of these models is aided by additional
information provided by the invention which allows the
5 identification of a subset of peptide amides on the protein's
binding surface which are likely to form hydrogen bonds with
acceptor residues on the cognate binding protein contact
surface. While most of the peptide amides present on the
native, uncomplexed protein or binding partner interaction
10 surfaces can be expected to be hydrogen bonded to other
portions of the same protein, a fraction of these peptide
amides, possibly approaching 50%, may be hydrogen bonded only
to solvent. As most protein-binding partner contact surfaces
are highly complementary to each other, it is likely that
15 upon complex formation solvent water is removed from the
interaction surfaces, and amides previously hydrogen bonded
to water will form new hydrogen bonds to the complementary
surface of the partner. This subset of binding surface
amides is readily identified in our studies (Step 8) as they
20 will have an exchange rate in the protein's native,
unliganded state of 0.5 seconds at pH 7.0 and 0°C. These
amides can form hydrogen bonds with the complementary surface
only if their hydrogens are oriented in the direction of the
complementary surface. This in turn places orientation
25 constraints on the entire associated peptide bond and to a
lesser degree the side chains of the two flanking amino acid
residues of each such amide. Application of these
constraints to the foregoing models of interaction surface
structure allow higher resolution modeling of the 3-
30 dimensional structure of the protein-binding partner ligand
interaction surfaces.

10. *Automation of the procedures required for the*
performance of enzymatic degradation and HPLC analysis under
35 *slowed tritium exchange conditions.*

While digestion and analysis procedures are performed at
0°C, analytical samples of tritium exchange-labeled peptides

- 47 -

must be stored at temperatures of approximately -60 to -80°C
if unacceptable losses of label from the peptide are to be
avoided over intervals of hours to weeks. Tritium exchange
continues in frozen samples in a manner inversely related to
5 temperature but effectively stops at temperatures of
approximately -70°C. At present, tritium exchange analysis
is performed by manually removing samples from -70°C storage,
melting them manually at 0°C, manual addition of reagents
(buffers, enzymes) and manual injection of samples onto the
10 HPLC column. These manipulations are labor intensive and
expose the samples to inadvertent heating during handling.
If HPLC-separated peptides are to be collected and stored for
future study, they are manually collected and stored at -
70°C. No presently available robotic HPLC autosampler has
15 the capability of performing the necessary manipulations on
samples stored in the frozen state.

A Spectraphysics AS3000® autosampler may be modified so
as to allow automation of these steps. These preferred
modifications were: inclusion of a solid dry ice bath in
20 which samples are stored until analysis; use of modified
fluidic syringes which operate reliably at 0°C; control of
the autosampler by an external computer; and placement of the
autosampler HPLC column and spectrophotometer within a 0°C
refrigerator. Under computerized control, the autosampler's
25 mechanical arm lifts the desired sample from the -70°C bath,
and places it in a heater/mixer which rapidly melts the
sample at 0°C. The liquified sample is then automatically
injected onto the HPLC column. Operation of HPLC pumps, on-
line radiation counter and data acquisition is similarly
30 automated.

To collect tritium-labeled, HPLC-separated peptides
under slowed exchange conditions, a Gilson-303® fraction
collector (also present in the 0°C refrigerator) has been
modified so that the sample collection tubes are immersed in
35 a dry ice bath. Computer-directed diversion of desired HPLC
effluent fractions into these prechilled tubes results in

rapid freezing of the desired tritium-labeled peptides to -
70°C.

Deuterium Exchange Embodiments:

5   In another embodiment, functionally labeled proteolytic
fragments, generated from a protein that has been
functionally labeled with deuterium (rather than tritium)
prior to receptor-ligand complex formation, are analyzed by
mass spectroscopy, conducted under conditions which minimize
10 off-exchange of peptide amide deuterium from peptide
fragments and allow the direct determination of the location
of functionally attached label within a peptide in the size
range 3-30 amino acids.

        Mass spectroscopy has become a standard technology by
15 which the amino acid sequence of proteolytically generated
peptides can be rapidly determined (43). It is commonly used
to study peptides which contain amino acids which have been
deuterated at carbon-hydrogen positions, and thereby
determine the precise location of the deuterated amino acid
20 within the peptide's primary sequence. This is possible
because mass spectroscopic techniques can detect the slight
increase in a particular amino acid's molecular weight due to
the heavier mass of deuterium. McCloskey, et al (44)
discloses use of deuterium exchange of proteins to study
25 conformational changes by mass spectrometry.

        The applicant has devised a deuterium-exchange technique
essentially identical, in steps 1-5, to the tritium exchange
technique described above except that on-exchange is
performed in deuterated water (preferably 80-99% mole
30 fraction deuterated water). This modified procedure, after
addition of binding partner and off-exchange, specifically
labels with exchanged deuterium the peptide amides which make
up the interaction surface between protein and binding
partner. Proteolytically generated fragments of protein
35 functionally labeled with deuterium are identified, isolated,
and then subjected to mass spectroscopy under conditions in
which the deuterium remains in place on the functionally

- 49 -

labeled peptide amides. Standard peptide sequence analysis
mass spectroscopy can be performed under conditions which
minimize peptide amide proton exchange: samples can be
maintained at 4°C to zero degrees C with the use of a
5 refrigerated sample introduction probe; samples can be
introduced in buffers which range in pH between 1 and 3; and
analyses are completed in a matter of minutes. MS ions may
be made by MALDI (matrix-assisted laser desorption
ionization) electrospray, fast atom bombardment (FAB), etc.
10 The carboxypeptidase may act before or simultaneously with
the ionization events. Subfragments are separated by mass
by, e.g., magnetic sector, quadropole, ion cyclotron, or
time-of-flight methods. For MS methods generally, see
Siuzdak, G., Mass Spectrometry for Biotechnology (Academic
15 Press 1996).

          Since deuterium is not radioactive, the deuterium-
labeled peptides must be identified by other means, such as
mass spectrometry (their molecular weight will be greater
than that of predicted for the same peptide without such a
20 label).

          If desired, the same binding protein: binding partner
complex may be studied both by tritium exchange (which need
only be to medium resolution) and by deuterium exchange. The
tritium exchange method will identify the relevant fragments.
25 Since the HPLC mobilities of these tritium-labeled fragments
will then be known, the corresponding deuterium-labeled
fragments can be identified by their common mobilities and
then subfragmented, etc.

          In a preferred embodiment, separate tritium and
30 deuterium exchange runs are avoided. Instead, the deuterated
water is supplemented with tritiated water, e.g. the solvent
is 98% mole fraction deuterated water and 2% mole fraction
tritiated water (e.g., 50 Ci/ml). As a result, the fragments
are labeled both with deuterium and tritium, and the relevant
35 fragments identified by their tritium-imparted radioactivity.
The subfragments are still analyzed by mass spectroscopy for
the presence of deuterated label (with appropriate correction

- 50 -

for the relatively small amount of tritium also present).
The purpose of the tritium is to radioactively tag peptide
fragments containing binding surface residues. However, the
exact residues involved are identified by MS analysis of
5 deuterium bearing peptides that have been further digested
with acid-reactive carboxypeptidases, allowing identification
of the deuterated residues of the radioactive peptides.

In a preferred embodiment, receptor-binding partner
complexes functionally labeled with deuterium and tritium at
10 their interaction surface are (under slowed exchanged
conditions as described above for high resolution tritium
exchange analysis) pepsin digested, subjected to rpHPLC in
0.1% TFA-containing buffers and column effluent containing
tritium labeled peptides subjected to mass spectroscopic
15 analysis. To more precisely localize the deuterium label
within each peptide, mass spectrometry is performed on
labeled-proteolytic fragments, that are progressively further
digested (under slowed exchange conditions) with acid-
reactive carboxypeptidases (41). This digestion can be
20 performed before introduction of the sample into the mass
spectrometer, or continuously *in situ* while the sample is
held in the mass spectrometer. As digestion proceeds,
molecular ions of each of the resulting enzyme-generated
carboxy-terminal truncated peptide subfragments is detected
25 by the mass spectrometer, and its molecular weight compared
to that known for the undeuterated form of the same peptide
fragment. Peptide fragments which bear functionally attached
deuterium are identified by an increase in their molecular
weight of one atomic unit when compared to the same peptide
30 fragment generated from undeuterated receptor-binding
partner. Sufficient subfragmentation and analysis as above
results in the deduction of the protease-generated fragments
that have functionally-bound deuterium. Thereby, the
location of each deuterated amide within the peptide is
35 determined.

In vivo Analysis.

In situ analysis of protein-binding partner interactions is possible *in vivo*. The protein, while present in its native environment as a component of an intact living cell, 5 or as a component of a cellular secretion such as blood plasma, is on-exchanged by incubating cells or plasma in physiologic buffers supplemented with tritiated (or deuterated) water. The binding partner is then added, allowed to complex to the cell or plasma-associated protein, 10 and then off-exchange initiated by returning the cell or plasma to physiologic conditions free of tritiated (or deuterated) water. During the off-exchange period (hours to days) the formed protein-binding partner complex is isolated from the cell or plasma by any purification procedure which 15 allows the complex to remain continuously intact. At the end of the appropriate off-exchange period, fragmentation and analysis of purified complex proceeds as above.

This analytic method is especially appropriate for proteins which lose substantial activity as a result of 20 purification, as the binding site is labeled prior to purification.

Binding Site Analysis by Indirect Hydrogen Exchange

In the methods described above, the entire surface of 25 the protein is labeled initially, and label is then removed from those surfaces which remain solvent exposed after formation of the complex of the binding protein and its binding partner. The binding site of the protein is occluded by the binding partner, and label is therefore retained at 30 this site.

When the complex is formed, the binding protein may undergo changes in conformation (allosteric changes) at other sites, too. If these changes result in segments of the protein being buried which, previously, were on the surface, 35 those segments will likewise retain label.

It is possible to distinguish binding site residues from residues protected from "off-exchange" by allosteric effects.

- 52 -

In essence, the binding partner, rather than the binding
protein, is labeled initially. The binding protein is
labeled indirectly as a result of transfer of label from the
binding partner to the binding protein. Such transfer will
5 occur principally at the binding surface.

      This procedure will functionally label receptor protein
amides if they are slowed by complex formation and are also
in intimate contact with the binding partner in the complexed
state. Receptor protein amides that are slowed because of
10 complex formation-induced allosteric changes in regions of
the protein which are not near the protein-binding partner
interaction surface will not be labeled. This procedure may
be performed as follows:

      1) binding partner is added to tritiated water
15 (preferably of high specific activity) to initiate tritium
exchange labeling of the binding partner.

      2) After sufficient labeling is achieved, binding
partner is separated from the excess of solvent tritium under
conditions which produce minimal loss of tritium label from
20 the binding partner. This can be accomplished by, e.g., a)
shifting the buffer conditions to those of slowed exchange
(0°C, acidic pH) followed by G-25 spin column separation of
the binding partner into tritium-free buffer or b) employing
stopped-flow techniques in which the on-exchange mixture is
25 rapidly diluted with large volumes of tritium free buffer.

      3) the tritium-labeled binding partner, now essentially
free of excess solvent tritium, is added to receptor protein
and conditions adjusted to allow spontaneous reversible
(equilibrium) complex formation to take place between the
30 two. The conditions of temperature and pH should also allow,
and preferably maximize, the specific transfer of tritium
label from the labelled binding partner to amides on the
binding protein's interaction surface with partner.
Typically, the pH will be 5-8 (conducive to ligand binding)
35 and the temperature 0-37°C. Initially, use of pH 7 and 22°C.
is recommended, the transfer being controlled by controlling
the incubation time. A typical trial incubation time would

- 53 -

be 24 hours. These conditions of pH, temperature and
incubation time may of course be varied.

    4) The complex is then incubated for periods of time
sufficient to allow transfer of tritium label from the
5 labeled binding partner to the receptor protein. During this
incubation period, tritium which has on-exchanged to regions
of the binding partner that are distant from the receptor-
binding partner interaction surface will leave the binding
partner by exchange with solvent hydrogen and be rapidly and
10 highly diluted in the large volume of solvent water, thereby
preventing its efficient subsequent interaction with the
binding protein. However, tritium label that has been
attached to binding partner amides present within the (newly
formed) protein-binding partner interaction surface will be
15 capable of exchanging off of the binding partner only during
the brief intervals when the interaction surface is exposed
to solvent water, i.e., when the complex is temporarily
dissociated. When so dissociated and solvent exposed, a
portion of tritium present on amides within the binding
20 partner's interaction surface will leave the surface and for
a brief time, remain within the proximity of the surface.
Given the rapid (essentially diffusion limited) rebinding of
binding protein and partner, much of the released tritium
that (briefly) remains within the environs of the partner's
25 binding surface will in part exchange with amides on the
(future) interaction surface of the approaching binding
protein molecule that subsequently binds to the binding
partner. Once such binding occurs, the transferred tritium
is again protected from exchange with solvent until the
30 complex dissociates again. The result will be the
progressive transfer of a portion of the tritium from the
binding partner interaction surface to exchangeable amides on
the cognate protein interaction surface.

    Amides whose exchange rates are conformationally slowed
35 each time complex formation occurs can also become labelled
with tritium, but they will do so at a much slower rate than
amides within the binding surface, as they are located more

- 54 -

distant from the high concentration of tritium "released" at
the interaction surface with each complex dissociation event.
The efficiency of transfer is roughly inversely proportional
to the cube of the distance between such conformational
5 changes and the binding surface.

The binding protein-tritiated binding partner complex
incubation conditions are adjusted to optimize specific
interaction surface amide tritium transfer (SISATT) for a
particular binding protein-partner pair. SISATT is defined
10 as the ratio of the amount of tritium (CPM) transferred from
binding partner to binding protein peptide amides previously
determined (by the technique of Claim 1) to undergo slowing
of amide hydrogen exchange upon binding-protein partner
complex formation divided by the total tritium (CPM)
15 transferred from binding partner to all peptide amides in the
binding protein.

5) After an incubation period that allows and preferably
maximizes SISATT, the conditions of slow hydrogen exchange
are restored, the complex is dissociated and the binding
20 protein fragmented. Fragments of binding protein (as opposed
to the initially labeled binding partner) that bear tritium
label are identified, and further characterized as previously
described.   Alternatively, deuterium is used instead of
tritium as the label. Deuterium has the advantage of
25 allowing a much higher loading of label (since deuterium is
much cheaper than tritium).

It is possible, also, to directly label the binding
partner with deuterium and the binding protein with tritium.
As a result, both the binding site and allosterically buried
30 amides of the binding protein will be tritiated, but only
binding site amides will be deuterated.

The indirect method is especially applicable to study of
proteins which undergo substantial conformation of changes
after, or in the course of binding, such as insulin and its
35 receptor.

- 55 -

Compositions

After determining the binding sites of a binding protein
or a binding partner, by the present methods (alone or in
conjunction with other methods), the information may be
5 exploited in the design of new diagnostic or therapeutic
agents. Such agents may be fragments corresponding
essentially to said binding sites (with suitable linkers to
hold them in the proper spatial relationship if the binding
site is discontinuous), or to peptidyl or non-peptidyl
10 analogues thereof with the similar or improved binding
properties. Or they may be molecules designed to bind to
said binding sites, which may, if desired, correspond to the
paratope of the binding partner.

The diagnostic agents may further comprise a suitable
15 label or support. The therapeutic agents may further
comprise a carrier that enhances delivery or other improves
the therapeutic effect.

The agents may present one or more epitopes, which may
be the same or different, and which may correspond to
20 epitopes of the same or different binding proteins or binding
partners.

Examples

As a demonstration of the practical use of this
25 technology, Applicant has studied the interaction of human
hemoglobin with two different monoclonal antibodies known to
be reactive with defined and previously identified subregions
of the hemoglobin binding protein haptoglobin. These studies
employed monoclonal antibody β6-1-23456 (specific for the
30 human hemoglobin β chain; epitope centered on or about β6-Glu
and monoclonal antibody β-121 (specific for the human
hemoglobin β chain in the region of residue β-121), both
antibodies being the generous gift of C.R. Kiefer, Medical
College of Georgia, Augusta, Georgia (51). Human haptoglobin
35 was obtained from Calbiochem Corporation, La Jolla,
California.

- 56 -

Preparation of hemoglobin: Blood was drawn from a
normal donor into sodium heparin at 10 U/ml. Red blood cells
were washed five times in cold phosphate buffered saline
(PBS) (pH 7.4) with the buffy coat aspirated after each wash.

5 An equal volume cold distilled water was added to the washed
cell pellet to lyse cells, and then a one-half volume of cold
toluene was added with vigorous vortexing. This mixture was
centrifuged for 30 minutes in a cold Sorvall® centrifuge
(Dupont) rotor at 15,000 rpm (33,000g). The hemoglobin

10 (middle) layer was removed and the centrifugation and
hemoglobin decantation repeated. The isolated hemoglobin was
dialyzed against four changes of cold 0.1M sodium phosphate,
0.5% NaCl pH 7.4. After dialysis, the sample was treated
with carbon monoxide for 15 minutes. Final hemoglobin

15 concentration was measured by using a molar extinction for
heme at 540 nm of 14,270. The preparation was stored frozen
in aliquots at -70°C.

Preparation of pepsin: Porcine pepsin (Worthington

20 Biochemical Corp.) was dissolved at 10 mg/ml in 50 mM sodium
acetate pH 4.5 and dialyzed against the same solution to
remove proteolytic fragments. It was stored frozen in
aliquots at -70°C.

25 *Tritium exchange:* All steps were performed at 0°C. On-
exchange was initiated by mixing equal volumes (5 μl) of
isolated hemoglobin (300 mg/ml) and tritiated water (50
Ci/ml) and the mixture incubated for four hours. Aliquots of
this mixture (1.3 μl) were then added to equimolar quantities

30 of either monoclonal β6, monoclonal β121, haptoglobin, (all
at 10 mg/ml in PBS, pH 7.4, in a final incubation volume of
75 μl) or added to 75 μl of PBS alone. These hemoglobin-
ligand mixtures were then immediately applied to 2 ml
Sephadex® G-25 spin columns and centrifuged 4 minutes at

35 1100g. Spin columns were prepared by filling 3 ml
polypropylene columns (Fisher Scientific) with 2 ml of
Sephadex G-25 fine equilibrated in PBS pH 7.4 plus 0.1%

Triton® X-100. Columns were pre-spun at 1100g for 2 minutes
just before use. After column separation, samples were off-
exchanged by incubation for a period of 40 hours, ten times
the length of on-exchange. Samples were then hydrolyzed with
5 pepsin. Typically, 25 μl of off-exchanged mixture containing
70 μg of hemoglobin was added to 10μg pepsin in 110μl of 0.1M
NaPO$_4$ pH 2.7 plus 2.5μl 0.5M H$_3$PO$_4$, the mixture incubated on
ice for 10 minutes and then injected onto the HPLC column.
An aliquot of on-exchanged hemoglobin was immediately
10 adjusted to pH 2.7, passed over a pH 2.7 (0.1 M NaPO$_4$ pH 2.7)
also proteolyzed and analyzed as above without a period of
off-exchange. To measure on-exchange rates of specifically
labeled amide protons, hemoglobin was on-exchanged as above
but with time intervals ranging from 10 sec. - 18 hours,
15 reacted with ligand, and off-exchanged for 18 hours. Samples
were then proteolyzed, subjected to HPLC as below, and
specific label on peptides quantified as a function of on-
exchange time.

20   _High pressure liquid chromatography:_ Digested samples
were analyzed on a Waters HPLC unit modified by putting the
column and injector under melting ice. Mobile phase was
prepared using Barnstead nanopure water, Aldrich ultrapure
sodium phosphate, J.T. Baker Ultrex® grade HCL and HPLC grade
25 acetonitrile from Burdick & Jackson. Mobile phase consisted
of 50 mM NaPO$_4$ pH 2.7 (solvent A) and a mixture of 20% 50 mM
NaPO$_4$ and 80% acetonitrile (ACN) final pH 2.7 (solvent B).
Separation of peptides was achieved using a 30 cm Phenomenex
Bondclone® 10 C18 column. The gradient program started at
30 100% A 0% B and altered the client to 83%A, 17%B over 3.4
minutes. From 3.4 to 6.7 minutes the system ran at a
constant 83%A, 17%B and from 6.7 to 73.3 minutes the program
implemented a linear increase in %B from 17% to 51%.
Absorbance was monitored at 214nm with a Waters model 441
35 detector.

- 58 -

For second dimension separation, peptide peaks bearing
specific label isolated as were collected at 0°C, stored
frozen at -70°C, thawed at 0°C, mixed with an equal volume of
100mM PO$_4$ pH 2.7, and subjected to HPLC as above, except that
5 buffer A was 0.115% trifluoracetic acid (TFA) in H$_2$O and
buffer B was 80% ACN, 20% H$_2$O, 0.1% TFA. Peaks bearing
specific radiolabel were identified and isolated.

Sample collection: HPLC effluent was collected at the
10 HPLC detector outflow with a Gilson model 203® fraction
collector. Samples (100 to 400 fractions per run) were
collected and radioactivity measured by adding five volumes
of Aquamix (ICN Radiochemicals) followed by scintillation
counting. In other studies, on-line liquid scintillation
15 counting was performed using a B-RAM flow radiation detector
(INUS Inc.).

Peptide identification: HPLC-isolated peptide were
analyzed by both gas phase Edman sequencing and amino acid
20 analysis at the UCSD protein sequencing facility.

RESULTS
    Hemoglobin-monoclonal antibody epitope mapping.
Hemoglobin was on-exchanged for 4 hours and then either
25 proteolyzed without a period of off exchange (FIG. 1b), mixed
with equimolar quantity of β6 monoclonal and then off-
exchanged for 40 hours (FIG. 1c), mixed with monoclonal β-121
and off-exchanged for 40 hours (data not shown) or off-
exchanged 40 hours in the absence of added antibody (FIG.
30 1d). When labeled hemoglobin is examined without a period of
off exchange (FIG. 1b), at least 17 radiolabeled peaks were
resolved, which generally corresponded to the peaks seen in
the optical density trace of the same HPLC run (FIG. 1a).
When labeled hemoglobin was allowed to fully off exchange
35 without the presence of a protecting monoclonal antibody, all
radiolabeled peaks disappeared (FIG. 1d). However, when
labeled hemoglobin was off-exchanged in the presence of the

- 59 -

β6 monoclonal, a single unique peak bearing radiolabel was
seen indicating that this fraction contains the β6 monoclonal
antigenic epitope (FIG. 1c).

When this peak was subjected to second dimension HPLC in
5   TFA-containing solvents under slowed proton exchange
conditions, two peptides were resolved by optical density at
214 nm, with only one of these bearing radiolabel (see FIG.
2). This label-bearing peptide was found by gas phase
microsequencing and amino acid analysis to represent residues
10 1-14 of the hemoglobin beta chain. Measurement of on-
exchange rates of labeled amides in this peptide demonstrated
two rate classes, both of equal size; one which exchanged on
with a half life of less than 10 seconds, and another with a
half life of approximately 1 hour. Specific activity
15 measurements indicate that 4.3 amide protons within this 14-
mer peptide are slowed by interaction of the β6 antibody with
hemoglobin. A synthetic peptide identical to residues 1-14
of the hemoglobin β chain (β1-14) was synthesized, tritium
labeled by proton exchange, and subjected to graded digestion
20 with carboxypeptidase-P (see FIGS. 6a-e).

Similar studies were performed with hemoglobin off-
exchanged after interaction with β-121 monoclonal (FIGS.
3a-c). Three pepsin-generated peptides were found to bear
tritium label (FIG. 3b). After second dimension HPLC
25 separation in TFA-containing solvents these peaks were
similarly resolved from contaminants, sequenced, and found to
be hemoglobin polypeptides β1-14, β113-128, and β15-31. In
preliminary proton counting studies, approximately two β121
monoclonal-slowed protons are present in each of these three
30 peptides.

The position of these peptidic regions in the folded
hemoglobin tetramer are shown in FIGS. 5a and 5b. The β6
monoclonal labels six amide bonds which are present on an
externally disposed segment of the folded hemoglobin molecule
35 (β chain amino acids 1-14) which includes the previously
characterized target epitope of this monoclonal (β6-9) (51).
The β-121 monoclonal labels a total of approximately six

protons which, though present on the non-contiguous regions
of the linear amino acid sequence of hemoglobin are seen to
be surface disposed and located in close proximity to each
other in the folded hemoglobin molecule, and include the
5   hemoglobin β chain 121 residue.

       Mapping of hemoglobin-haptoglobin interaction sites:
When hemoglobin binds to haptoglobin it is known that the
hemoglobin molecule contacts haptoglobin through three non-
10 contiguous peptidic regions which consist of hemoglobin α
chain 121-127, β 11-25 and β 131-146 (52,53). We therefore
anticipated that pepsin cleavage of hemoglobin labeled at
haptoglobin interaction sites would display between 2 and 10
radiolabeled peptides. We therefore performed our
15 haptoglobin studies at a higher level of resolution,
accomplished by collection of a larger number of HPLC
fractions (see FIGS. 4a-d). Under these conditions, labeled
hemoglobin analyzed without a period of off exchange
demonstrates greater than 33 discernable radiolabeled peaks
20 (FIG. 4b), which again correspond to the optical density
tracing (FIG. 4a). Labeled hemoglobin off-exchanged in the
presence of haptoglobin produces 7 specifically radiolabeled
peaks (FIG. 4c) which are not present if hemoglobin is off-
exchanged in the absence of haptoglobin (FIG. 4d). These
25 results indicate that this technology works well with a
receptor-like ligand interaction system as complex as that of
hemoglobin with haptoglobin.

       Solvent Effect
30   Synthetic hemoglobin β1-14 peptide was tritium-labeled
at all peptide amides by proton exchange, and aliquots of
labeled peptide subjected to 0°C HPLC analysis as in FIGS.
1a-d except that a range of solvent pH's were utilized as
indicated below. The percent of original peptide-bound
35 tritium that remained bound to the peptide under each HPLC
condition was then determined.

- 61 -

pH	A solvent	B solvent
2.1	0.115% TFA in water	80% ACN, 20% H_2O, 0.1% TFA
2.7	50 mM PO_4, pH 2.7	80% ACN, 20% 50 mM PO_4, pH 2.7
3.5	50 mM PO_4, pH 3.5	80% ACN, 20% 50 mM PO_4, pH 3.5
4.0	50 mM PO_4, pH 4.0	80% ACN, 20% 50 mM PO_4, pH 4.0

5

Tritium retention was about 57% for TFA (pH 2.1), 46% for PO_4 (pH 2.7), 34% for PO_4 (pH 3.5), and 14% for PO_4 (pH 4.0).

The invention is not to be limited in scope by the

10 specific embodiments described which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein,

15 will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All references cited herein are incorporated in their

20 entireties by reference for all purposes.

25

30

35

REFERENCES

1. Horsfall, A.C., et al., Epitope mapping. _Immunology Today_ 12:211-213, 1991.

2. Arnon, R., et al., Structural basis of antigenic specificity and design of new vaccines. _FASEB J_ 6:3265-3274, 1992.

3. Englander, S.W., et al., The assignment of proton resonances in 2D NMR spectra of proteins. _Techniques in Protein Chemistry_, TE Hughim ed. Academic Press, San Diego, pg 207-222, 1989.

4. Englander, S.W., et al., Hydrogen--Tritium exchange. _Methods in Enzymology_ 49:24-39, 1978.

5. Englander, S.W., et al., Hydrogen-tritium exchange. _Methods in Enzymology_ 26:406-413, 1972.

6. Englander, J.J., et al., Protein hydrogen exchange studied by the fragment separation method. _Analytical Biochemistry_ 147:234-244, 1985.

7. Englander, S.W., et al., Hydrogen-tritium exchange of the random chain polypeptide. _Biopolymers_ 7:379-393, 1969.

8. Molday, R.S., et al., Primary structure effects on peptide group hydrogen exchange. _Biochemistry_ 11:150, 1972.

9. Kim, P.S., et al., Influence of charge on the rate of amide proton exchange. _Biochemistry_ 21:1, 1982.

10. Bai, Y., et al., Primary structure effects on peptide group hydrogen exchange. _Proteins: Structure, Function, and Genetics_ 17:75-86, 1993.

11. Connelly, G.P., et al., Isotope effects in peptide group hydrogen exchange. _Proteins: Structure, Function, and Genetics_ 17:87-92, 1993.

12. Englander, S.W., et al., Hydrogen exchange studies or respiratory proteins. III. Structural and free energy changes in hemoglobin by use of a difference method. _J. Biol. Chem._ 248:4852-4861, 1973.

13. Englander, J.J., Hydrogen-tritium exchange survey of
     allosteric effects in hemoglobin. Biochemistry 26:1846-
     1850, 1987.

14. Louie, G., et al., Salt, phosphate and the Bohr effect
5   at the haemoglobin beta chain C terminus studied by
     hydrogen exchange. J. Mol. Biol. 201:765-772, 1988.

15. Rosa, J.J., et al., An experimental proceudre for
     increasing the structural resolution of chemical
     hydrogen-exchange measurements on proteins: Application
10   to ribonuclease S peptide. J. Mol. Biol. 133:399-416,
     1979.

16. Rosa, J.J., et al., Hydrogen exchange from identified
     regions of the S-protein component of ribonuclease as a
     function of temperature, pH, and the binding of S-
15   peptide. J. Mol. Biol. 145:835-851, 1981.

17. Rosa, J.J., et al., Effects of binding of S-peptide and
     2'-cytidine monophosphate on hydrogen exchange from the
     S-protein component of ribonuclease S. J. Mol. Biol.
     160:517-530, 1982.

20 18. Englander, S.W., et al., Individual breathing reactions
     measured in hemoglobin by hydrogen exchange methods.
     Biophys. J. 10:577, 1979.

19. Rogero, J.R., et al., Individual breathing reactions
     measured by functional labeling and hydrogen exchange
25   methods. Methods in Enzymology 131:508-517, 1986.

20. Ray, J., et al., Allosteric sensitivity in hemoglobin at
     the a-subunit N-terminus studied byhydrogen exchange.
     Biochemistry 25:3000-30007, 1986.

21. Louie, G., et al., Allosteric energy at the hemoglobin
30   beta chain C terminus studied by hydrogen exchange. J.
     Mol. Biol. 201:755-764, 1988.

22. Burz, D.S., et al., Mapping structure perturbation in
     escherichia coli aspartate transcarbamylase by medium
     resolution hydrogen exchange. Biophys. J. 49:70-72,
35   1986.

23. Mallikarachchi, D., et al., Effects of ATP and CTP on
     the conformation of the regulatory subunit of

- 64 -

escherichia coli aspartate transcarbamylase in solution:
A medium-resolution hydrogen exchange study.
Biochemistry 28:5386-5391, 1989.

24. Beasty, A.M., et al., Characterization of an early
5   intermediate in the folding of the a subunit of
tryptophan synthase by hydrogen exchange measurement.
Biochemistry 24:3547-3553, 1985.

25. Fromajeot, et al., US Patent 3,828,102. Method for
preparation of tritium labeled proteins. Filed
10   September 19, 1972, issued August 1974.

26. Benson. US Patent 3,560,158 and 3,623,840. Method for
analysis of labile hydrogen containing compounds. Filed
August 12, 1965, issued February 2, 1971.

27. Fesik, et al., Biochem Biophys Res Comm 147(3):892-898,
15   1987.

28. Paterson, Y., et al., An antibody binding site on
cytochrome c defined by hydrogen exchange and two-
dimensional NMR. Science 249:755-759, 1990.

29. Mayne, L., et al., Effect of antibody binding on protein
20   motions studied by hydrogen-exchange labeling and two-
dimensional NMR. Biochemistry 31:10678-10685, 1992.

30. Benjamin, D.C., et al., Long-range changes in a protein
antigen due to antigen-antibody interaction.
Biochemistry 31:9539-9545, 1992.

25 31. Ruegg, Uth, et al., Reductive cleavage of cystine
disulfides with tributyl phosphine. Meth Enzymol
47:111-117, 1977.

32. Kirley, T.L., Reduction and fluorescent labeling of
cyst(e)ine-containing proteins for subsequent structural
30   analyses. Anal Biochem 180:231, 1989.

33. Burns, J.A., et al., Selective reduction of disulfides
by Tris (2-carboxyethyl) phosphine. J Org Chem 56:2648-
2650, 1991.

34. Levison, M.E., et al., Reduction of biological
35   substances by water-soluble phosphines: Gamma globulin
(IgG). Experientia 25:126-127, 1969.

- 65 -

35. Gray, W.R., Disulfide structures of highly bridged peptides: A new strategy for analysis. _Protein Science_ 2:1732-1748, 1993.

36. Gray, W.R., Echistatin disulfide bridges: Selective reduction and linkage assignment. _Protein Science_ 2:1479-1755, 1993.

37. Takayuki, T., et al., Cathepsin D from porcine and bovine spleen. _Methods in Enzymology_ 80:565-581, 1981.

37a. Krishnan, S., et al., Purification of an acid protease and a serine carboxypeptidase from Aspergillus niger using metal-chelate affinity chromatography. _J Chromatography_ 329:165-170, 1985.

37b. Xiaoming, L., et al., A novel carboxylesterase from aspergillus niger and its hydrolysis of succinimide esters. _Carlsberg Res Commun_ 54:241-249, 1989.

37c. Zhu, H., et al., Purification and characterization of an extracellular acid proteinase from the ectomycorrhizal fungus _Hebeloma crustuliniforme_. _Applied Environmental Microbiology_ 56:837-843, 1990.

38. Fusek, M., et al., Enzymic properties of thermopsin. _J Biol Chem_ 265:1496-1501, 1990.

39. Breddam, K.. Serine carboxypeptidases. A review. _Carlsberg Res Commun_ 51:83-128, 1986.

40. Tsugita, A., Developments in protein microsequencing. _Adv Biophys_ 23:81-113, 1987.

40a. Byrne, R.H., et al., An improved freeze-drying technique for the study of hydrogen exchange of proteins and polypeptides. _Analytical Biochemistry_ 33:414-428, 1970.

40b. Schreier, A.A., et al., Concentration-dependent hydrogen exchange kinetics of ^{3}H-labeled S-peptide in ribonuclease S. _J Mol Biol_ 105:409-426, 1976.

41. Smith, C.E., et al., Carboxy-terminal protein sequence analysis using carboxypeptidase P and electrospray mass spectrometry. _Techniques in Protein Chemistry IV_, pg 463, 1993.

42. Rosuack, K.J., et al., C-terminal sequencing of peptides
     using electrospray ionization mass spectrometry. Rapid
     Communications in Mass Spectrometry 6:637-640, 1992.

43. Loo, J.A., et al., Primary sequence information from
5   intact proteins by electrospray ionization tandem mass
     spectrometry. Science 248:201-204, 1990.

44. McCloskey, J.A., Introduction of deuterium by exchange
     for measurement by mass spectrometry. Methods in
     Enzymology 193:329-338, 1990.

10 45. Thevenon-Emeric, G., et al., Determination of amide
     hydrogen exchange rates in peptides by mass
     spectrometry. Anal Chem 64:2456-2458, 1992.

46. Winger, B.E., et al., Probing qualitative conformation
     differences of multiply protonated gas-phase proteins
15   via H/D isotopic exchange with D$_2$O. J Am Chem Soc
     114:5897-5989, 1992.

47. Zhang, Z., et al., Determination of amide hydrogen
     exchange by mass spectrometry: A new tool for protein
     structure elucidation. Protein Science 2:522-531, 1993.

20 48. Katta, V., et al., Hydrogen/Deuterium exchange
     electrospray ionization mass spectrometry: A method for
     probing protein conformational changes in solution. J
     Am Chem Soc 115:6317-6321, 1993.

49. Chi, H.T., et al., Use of deuterium-hydrogen exchange to
25   characterize the fragmentation pathways of arteether and
     its metabolites in a thermospray mass spectrometer.
     Organic Mass Spectrometry 28:17-17, 1993.

50. Sepetov, N.F., et al., The use of hydrogen-deuterium
     exchange to facilitate peptide sequencing by
30   electrospray tandem mass spectrometry. Rapid
     Communication in Mass Spectrometry 7:58-62, 1993.

51. Kiefer, C.R. et al., Negative screening for sickle cell
     diseases with a monoclonal immunoassay on newborn blood
     eluted from filter paper. J. Lab. Clin. Med. 116:826-
35   830, 1990.

52. Yoshioka, N. et al., Haemoglobin binding with
     haptoglobin. Biochem. J. 234:453-456, 1986.

53. McCormick, D.J., et al., Hemoglobin binding with haptoglobin: Delineation of the haptoglobin binding site on the a-chain of human hemoglobin. _J. Protein Chem._ _9_:735, 1990.

5 54. Tsugita, A. et al., Reaction of pentafluoropropionic anhydride vapor on polypeptide as revealed by mass spectrometry. A carboxypeptidase mimetic degradation. _Chemistry Letters_ _235_-238, 1992.

55. Tsugita, A., et al., Development of novel c-terminal
10   sequencing methods. _Methods in Protein Sequence Analysis_, edited by K Imahori, F Sakiyama, Plenum Press, New York, 1993, pp. 55.

15

20

25

30

35

What Is Claimed Is:

    1.   A method of determining, at a resolution of about
1-5 amino acid residues, the position of a labeled peptide
5 amide group in a polypeptide, said method comprising the
steps of:

        (a)   progressively degrading, under conditions of
slow hydrogen exchange, a polypeptide of known or
determinable amino acid sequence in which at least one
10 peptide amide group is labeled with a heavy hydrogen, into a
series of subfragments, wherein each subfragment in the
series is composed of about 1-5 fewer amino acid residues
than the preceding subfragment in the series;

        (b)   quantifying the amount of heavy hydrogen label
15 associated with each subfragment; and

        (c)   correlating the amount of heavy hydrogen label
of the subfragments with the amino acid sequence of the
polypeptide, thereby localizing the position of the labeled
peptide amide group in the polypeptide to a within about 1-5
20 amino acid residues.

    2.   A method of determining, at a resolution of about
1-5 amino acid residues, the position of a labeled peptide
amide group in a polypeptide, said method comprising the
25 steps of:

        (a)   fragmenting, under conditions of slow
exchange, a polypeptide of known or determinable amino acid
sequence in which at least one peptide amide group is labeled
with a heavy hydrogen, into a plurality of fragments;

30   (b)   determining, under conditions of slow hydrogen
exchange, which of said fragments are labeled with heavy
hydrogen;

        (c)   progressively degrading each of said labeled
fragments under conditions of slow hydrogen exchange to
35 obtain a series of subfragments, wherein each subfragment in
the series is composed of about 1-5 fewer amino acid residues
than the preceding subfragment in the series;

- 69 -

(d)   quantifying the amount of heavy hydrogen label associated with each subfragment; and

(e)   correlating the amount of heavy hydrogen label of the subfragments with the amino acid sequence of the
5 labeled fragment, thereby localizing the position of the labeled peptide amide in the fragment to a within about 1-5 amino acid residues.

3.   The method of Claim 1 or 2 in which the heavy
10 hydrogen label is tritium and the presence or amount of heavy hydrogen label on a fragment or subfragment is determined by radioactivity measurements.

4.   The method of Claim 1 or 2 in which the heavy
15 hydrogen label is deuterium and the presence or amount of heavy hydrogen label on a fragment or subfragment is determined by measuring the mass of the subfragment.

5.   The method of Claim 1 or 2 in which the labeled
20 polypeptide is denatured under conditions of slow hydrogen exchange prior to step (a).

6.   The method of Claim 1 or 2 in which any disulfide bridges in the labeled polypeptide are disrupted under
25 conditions of slow hydrogen exchange prior to step (a).

7.   The method of Claim 6 in which the disulfide bridges are disrupted by contacting the labeled polypeptide with a water soluble phosphine.
30
8.   The method of Claim 1 or 2 in which the progressive degradation comprises contacting the labeled polypeptide with an acid-resistant carboxypeptidase selected from the group consisting of carboxypeptidase P, carboxypeptidase Y,
35 carboxypeptidase W and carboxypeptidase C.

- 70 -

9.   The method of Claim 8 in which the acid-resistant
carboxypeptidase is carboxypeptidase P.

10.   The method of Claim 1 or 2 in which the progressive
5 degradation comprises contacting the labeled polypeptide with
pentafluoropropionic acid.

11.   The method of Claim 1 or 2 in which the slow
hydrogen exchange conditions comprise a pH in the range of 2-
10 3 and a temperature in the range of 0-10°C.

12.   The method of Claim 11 in which the pH is about 2.7
and the temperature is about 0°C.

15   13.   A method of determining, at a resolution of about
1-5 amino acid residues, which peptide amide groups in a
polypeptide of interest are accessible to solvent, said
method comprising the steps of:
          (a)   contacting a polypeptide of known or
20 determinable amino acid sequence with heavy hydrogen under
conditions wherein peptide amide hydrogens of the polypeptide
which are freely accessible to solvent exchange with, and
become selectively labeled by, heavy hydrogen;
          (b)   progressively degrading the selectively
25 labeled polypeptide under conditions of slow hydrogen
exchange into a series of subfragments, wherein each
subfragment in the series is composed of about 1-5 fewer
amino acid residues than the preceding subfragment in the
series;
30   (c)   quantifying the amount of heavy hydrogen label
associated with each subfragment; and
          (d)   correlating the amount of heavy hydrogen label
of the subfragments with the amino acid sequence of the
polypeptide, thereby localizing the position of the labeled
35 peptide amide group in the polypeptide to within about 1-5
amino acid residues.

14. A method of determining, at a resolution of about
1-5 amino acid residues, which peptide amide groups in a
polypeptide of interest are accessible to solvent, said
method comprising the steps of:

5   (a) contacting a polypeptide of known or
determinable amino acid sequence with heavy hydrogen under
conditions wherein peptide amide hydrogens in the polypeptide
which are freely accessible to solvent exchange with, and
become selectively labeled by, heavy hydrogen;

10   (b) fragmenting the selectively labeled
polypeptide under conditions of slow hydrogen exchange into a
plurality of fragments;

            (c) determining, under conditions of slow hydrogen
exchange, which of said fragments are labeled with heavy

15 hydrogen;

            (d) progressively degrading each of said labeled
fragments under conditions of slow hydrogen exchange into a
series of subfragments, wherein each subfragment in the
series is composed of about 1-5 fewer amino acid residues

20 than the preceding subfragment in the series;

            (e) quantifying the amount of heavy hydrogen label
associated with each subfragment; and

            (f) correlating the amount of heavy hydrogen label
of the subfragments with the amino acid sequence of the

25 labeled fragment, thereby localizing the position of the
labeled peptide amide in the fragment to a within about 1-5
amino acid residues.

     15. The method of Claim 13 or 14 in which the heavy

30 hydrogen label is tritium and the presence or amount of heavy
hydrogen label on a fragment or subfragment is determined by
radioactivity measurements.

     16. The method of Claim 13 or 14 in which the heavy

35 hydrogen label is deuterium and the presence or amount of
heavy hydrogen label on a fragment or subfragment is
determined by measuring the mass of the subfragment.

- 72 -

17.   The method of Claim 13 or 14 in which the labeled
polypeptide is denatured under conditions of slow hydrogen
exchange prior to step (a).

5   18.   The method of Claim 13 or 14 in which any disulfide
bridges in the labeled polypeptide are disrupted under
conditions of slow hydrogen exchange prior to step (a).

19.   The method of Claim 18 in which the disulfide
10 bridges are disrupted by contacting the labeled polypeptide
with a water soluble phosphine.

20.   The method of Claim 13 or 14 in which the
progressive degradation comprises contacting the labeled
15 polypeptide with an acid-resistant carboxypeptidase selected
from the group consisting of carboxypeptidase P,
carboxypeptidase Y, carboxypeptidase W and carboxypeptidase
C.

20   21.   The method of Claim 20 in which the acid-resistant
carboxypeptidase is carboxypeptidase P.

22.   The method of Claim 13 or 14 in which the
progressive degradation comprises contacting the labeled
25 polypeptide with pentafluoropropionic acid.

23.   The method of Claim 13 or 14 in which the slow
hydrogen exchange conditions comprise a pH in the range of 2-
3 and a temperature in the range of 0-10°C.
30

24.   The method of Claim 23 in which the pH is about 2.7
and the temperature is about 0°C.

25.   A method of characterizing a binding site of a
35 binding protein of known or determinable amino acid sequence,
said method comprising the steps of:

(a)   selectively labeling peptide amide hydrogens of a binding protein that are substantially protected from exchange with solvent hydrogens when the binding protein binds its binding partner;

5   (b)   progressively degrading, under conditions of slow hydrogen exchange, the selectively labeled binding protein to obtain a series of subfragments, wherein each subfragment of the series is composed of about 1-5 fewer amino acid residues than the preceding subfragment in the

10 series;

(c)   quantifying the amount of label associated with each subfragment; and

(f)   correlating the amount of label of the subfragments with the amino acid sequence of the binding

15 protein, thereby localizing the positions of the binding protein that had been labeled to within about 1-5 amino acid residues and thus characterizing the binding site of the binding protein.

20   26. A method of characterizing a binding site of a binding protein of known or determinable amino acid sequence, said method comprising the steps of:

(a)   selectively labeling peptide amide groups of a binding protein that are substantially inaccessible to

25 solvent when the binding protein binds its binding partner so as to obtain a selectively labeled binding protein wherein either (i) the solvent inaccessible peptide amide groups of the binding protein comprise a heavy hydrogen and the solvent inaccessible peptide amide groups comprise a normal hydrogen

30 or (ii) the solvent inaccessible peptide amide groups of the binding protein comprise a normal hydrogen and the solvent inaccessible peptide amide groups comprise a heavy hydrogen;

(b)   fragmenting the selectively labeled binding protein into a plurality of fragments under conditions of

35 slow hydrogen exchange;

(c)   determining which fragments are labeled with heavy hydrogen;

- 74 -

(d)   progressively degrading, under conditions of
slow hydrogen exchange, each of the heavy hydrogen-labeled
fragments to obtain a series of subfragments, wherein each
subfragment of the series is composed of about 1-5 fewer
5 amino acid residues than the preceding subfragment in the
series;

(e)   quantifying the amount of heavy hydrogen
associated with each subfragment; and

(f)   correlating the amount of heavy hydrogen of
10 the subfragments with the amino acid sequences of the
fragments from which the subfragments were generated, thereby
localizing the positions of the fragment that had been
labeled with heavy hydrogen to a resolution about 1-5 amino
acid residues, and thus characterizing the binding site of
15 the binding protein.

27.   The method of Claim 25 or 26 in which the binding
protein is selectively labeled by a method which comprises
the steps of:
20   (i)   contacting the binding protein with a binding
partner under conditions wherein the binding protein binds
the binding partner so as to form a binding protein-binding
partner complex; and

(ii)   contacting the complex with a heavy hydrogen-
25 labeled solvent under conditions of rapid hydrogen exchange
for an "on-exchange" period sufficient for solvent-accessible
peptide amide hydrogens of the complex to exchange with, and
be substantially replaced by, heavy hydrogens of the solvent,
in a detectable number of molecules of the complex.
30

28.   The method of Claim 25 or 26 in which the binding
protein is selectively labeled by a method which comprises
the steps of:

(i)   contacting the binding protein with a heavy
35 hydrogen-labeled solvent under conditions of rapid hydrogen
exchange for an "on-exchange" period sufficient for solvent-
accessible peptide amide hydrogens of the binding protein to

- 75 -

exchange with, and be substantially replaced by, heavy
hydrogens of the solvent, in a detectable number of molecules
of the binding protein;

(ii)   contacting the binding protein with a binding
5 partner under conditions wherein the heavy hydrogen labels
are substantially retained and wherein the binding protein
binds the binding partner so as to form a binding protein-
binding partner complex; and

(iii)   contacting the complex with a solvent that
10 is substantially free of heavy hydrogen under rapid exchange
conditions for an "off-exchange" period sufficient for
solvent-accessible peptide amide hydrogens or heavy hydrogens
of the complex to exchange with, and be substantially
replaced by, normal hydrogen of the solvent.
15

29.   The method of Claim 28 in which the heavy hydrogen
is tritium and the presence or amount of heavy hydrogen on a
fragment or subfragment is determined by radioactivity
measurements.
20

30.   The method of Claim 28 in which the heavy hydrogen
is deuterium and the presence or amount of heavy hydrogen on
a fragment or subfragment is determined by measuring the mass
of the fragment or subfragment.
25

31.   The method of Claim 2, 14 or 26, further including
the step of separating the fragments prior to determining
which fragments are labeled with heavy hydrogen.

30   32.   The method of Claim 31 in which the separation
comprises two sequential separations steps which are carried
out under different conditions.

33.   The method of Claim 32 in which the first
35 sequential separation step is carried out at a pH in the
range of pH 2.1 to pH 3.0 and the sequential separation is
carried out at a pH in the range of pH 2.1 to pH 3.0, where

- 76 -

the pH of the first and second sequential separation steps
are different.

34.   The method of Claim 33, in which the first
5   sequential separation step is carried out at a pH of 2.7 and
the second sequential separation step is carried out at a pH
of 2.1.

35.   The method of Claim 28 in which the degradation of
10   the selectively labeled binding protein or labeled fragments
comprises contacting the selectively labeled binding protein
or labeled fragments with an acid resistant carboxypeptidase
selected from the group consisting of carboxypeptidase P,
carboxypeptidase Y, carboxypeptidase W and carboxypeptidase
15   C.

36.   The method of Claim 28 in which the degradation of
the selectively labeled binding protein or labeled fragments
comprises contacting the selectively labeled binding protein
20   or labeled fragments with pentafluoropropionic acid
anhydride.

37.   The method of Claim 28 in which any disulfide
bridges in the selectively labeled binding protein are
25   disrupted under conditions of slow hydrogen exchange prior to
fragmentation or progressive subfragmentation.

38.   The method of Claim 37 in which the disulfide
bridges are disrupted by contacting the selectively labeled
30   binding protein with a water-soluble phosphine.

39.   The method of Claim 28 where prior to fragmentation
or subfragmentation, the selectively-labeled binding protein
is denatured under conditions of slow hydrogen exchange.
35

40.   The method of Claim 39 in which the denaturation is
carried out in a solvent such that the pH for minimization of

- 77 -

hydrogen exchange is substantially higher than that of a
purely aqueous solution.

41.　The method of Claim 40 in which the solvent
5　comprises about 5-20% water and the remainder is a nonaqueous
polar solvent.

42.　The method of Claim 41 in which the nonaqueous
polar solvent is selected from the group consisting of
10　acetonitrile, dimethyl sulfoxide, a polyol and combinations
thereof.

43.　The method of Claim 42 in which the polyol is
glycerol.
15

44.　The method of Claim 41 in which the solvent further
includes about 2-4 M guanidine thiocyanate.

45.　The method of Claim 41, wherein the pH of the
20　solvent is pH 4.8 - 5.2.

25

30

35

Fig. 1a
HLPC OD
TRACING

Fig. 1b.
HEMOGLOBIN ALONE
4 hr on, 0 hr off

Fig. 1C.

HEMOGLOBIN 4 hr on,
add monoclonal β6,
40 hr off

Fig. 1d.

HEMOGLOBIN ALONE
4 hr on, 40 hr off

Fig. 2.

Fig. 3a.

HEMOGLOBIN ALONE
4 hr on, 0 hr off

Fig. 3b.

HEMOGLOBIN 4 hr on,
add monoclonal β121,
40 hr off

β1-14　β113-128

β15-31

Fig. 3C.

HEMOGLOBIN ALONE
4 hr on, 40 hr off

FRACTION NUMBER

Fig. 4a.

HLPC OD TRACING

Fig. 4b.

HEMOGLOBIN ALONE
4 hr on, 0 hr off

Fig. 4c.

HEMOGLOBIN 4 hr on,
add haptoglobin,
40 hr off

Fig. 4d.

HEMOGLOBIN ALONE
4 hr on, 40 hr off

FRACTION NUMBER

SUBSTITUTE SHEET (RULE 26)

Fig. 5a.
Hb plus β6 Monoclonal

β6

β1-14

Fig. 5b.
Hb plus β121 Monoclonal

β15-31

β121

β113-128

β1-14

SUBSTITUTE SHEET (RULE 26)

Fig. 6a. NO DIGESTION

Fig. 6b CP-P 0.1 MG/ML 2.5 MIN. 0°C

Fig. 6c. CP-P 0.5. MG/ML 2.5MIN. 0°C

Fig. 6d.

CP-P
1.0 MG/ML
5 MIN   0°C

Fig. 6e.

CP-P
1.0 MG/ML
15 MIN   0°C

Fig. 7a.

Fig. 7b.

Fig. 7c.

Fig. 7d.

Fig. 7e.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17135

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/00, 1/68; G01N 33/53
US CL :435/4, 6, 7.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 6, 7.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US 5,658,739 A (WOODS, JR.) 19 August 1997 (19,08,97), see entire document, especially the background of the invention and references cited.	1-45
Y	PATERSON, Y. et al. An antibody binding site on cytochrome c defined by hydrogen exchange and two dimensional NMR. Science. 17 August 1990, Vol. 249, pages 755-759, see entire document.	1-45
Y	ENGLANDER et al., Protein hydrogen exchange studied by the fragment separation method. Analytical Biochemistry. 1985. Vol. 147, pages 234-244.	1-45

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

*	Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	
"E"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	
"P"	document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
25 SEPTEMBER 1998	20 OCT 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer JOSEPH W. RICIGLIANO
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Europäisches Patentamt	European Patent Office	Office européen des brevets
Zweigstelle in Den Haag Recherchen-abteilung	Branch at The Hague Search division	Département à La Haye Division de la recherche

Reinhard – Skuhra – Weise & Partner
Postfach 44 01 51
80750 München
ALLEMAGNE

E i n g e g a n g e n
Reinhard • Skuhra • Weise

– 3. Nov. 2004

Frist _int. 03.12.2004_ Erl. _uUOle_

Datum/Date
03.11.04

Zeichen/Ref./Réf.	Anmeldung Nr./Application No./Demande n°./Patent Nr./Patent No./Brevet n°.
P14921 DrB/bin	01928981.8-2404-US0113907

Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire
Duke University

COMMUNICATION

The European Patent Office herewith transmits as an enclosure the European search report for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

[X] Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.

REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 00/16100 A (THERMAPHORE SCIENCES INC) 23 March 2000 (2000-03-23) * page 5; claims 51,55 * * paragraph '4.2.2.! * * paragraph '4.5.! *	1-33	G01N33/00 G01N33/537 G01N33/68
X	VILLANUEVA J ET AL: "Hydrogen exchange monitored by MALDI-TOF mass spectrometry for rapid characterization of the stability and conformation of proteins" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 472, no. 1, 21 April 2000 (2000-04-21), pages 27-33, XP004337035 ISSN: 0014-5793 * page 32 *	1-33	
X	WO 99/09204 A (WOODS VIRGIL L JR) 25 February 1999 (1999-02-25) * page 1, lines 16-23; claims 4,5,25,28,39 *	1-6	
X	BUIJS J ET AL: "Conformational stability of adsorbed insulin studied with mass spectrometry and hydrogen exchange." ANALYTICAL CHEMISTRY. 1 AUG 1999, vol. 71, no. 15, 1 August 1999 (1999-08-01), pages 3219-3225, XP002300594 ISSN: 0003-2700 * page 3225 *	1	

TECHNICAL FIELDS SEARCHED (Int.Cl.7)

G01N

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

1

Place of search	Date of completion of the search	Examiner
Munich	13 October 2004	Cuendet, P

EPO FORM 1503 03.82 (P04C04)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 92 8981

This annex lists the patent family members relating to the patent documents cited in the above—mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-10-2004

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0016100	A	23-03-2000	AT	244405 T	15-07-2003
			AU	5924699 A	03-04-2000
			CA	2347419 A1	23-03-2000
			DE	69909312 D1	07-08-2003
			DE	69909312 T2	22-04-2004
			DK	1121594 T3	27-10-2003
			EP	1121594 A1	08-08-2001
			WO	0016100 A1	23-03-2000
			US	2002197650 A1	26-12-2002
			US	6599707 B1	29-07-2003
WO 9909204	A	25-02-1999	US	6291189 B1	18-09-2001
			AT	265542 T	15-05-2004
			AU	8913498 A	08-03-1999
			CA	2300100 A1	25-02-1999
			DE	69823525 D1	03-06-2004
			EP	1012325 A1	28-06-2000
			WO	9909204 A1	25-02-1999
			US	2002042080 A1	11-04-2002